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Human soft tissue sarcomas (STS), particularly their most common type, 
undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous 
histiocytoma (MFH), frequently carry mutations in P53 and RB tumor suppressor 
genes. We have established mouse model of STS by using Cre-loxP-mediated 
conditional inactivation of p53 and Rb tumor suppressor genes in the connective tissue 
cells of the dermis. Similar to human STS, the majority of sarcomas in this model are 
UPS and overexpress Cxcr4, which contributes to their invasive properties. By using 
irradiation chimeras that have been generated by transplanting bone marrow cells from 
mice carrying the Rosa26StoploxPLacZ or the Z/EG reporter, as well as floxed p53 and 
Rb genes, to irradiated p53loxP/loxPRbloxP/loxP mice, we have determined that sarcomas 
originate from the local resident cells. Notably, isolated mesenchymal multipotent 
cells characterized by strict plastic adherence and low levels of Sca-1 expression have 
shown enhanced potential for malignant transformation according to invasion, soft 
agar and tumorigenicity assay following conditional inactivation of p53 and Rb. Taken 
together, our results indicate that local Sca-1low dermal mesenchymal stem/progenitor 
cells may be a preferential target for malignant transformation associated with p53 and 
Rb deficiency. 
As the next step towards imaging of STS formation, we have evaluated 
applicability of highly fluorescent core-shell silica nanoparticles, known as C dots, for 
in vivo applications. We have demonstrated C dots are not toxic and can be used in a 
 broad range of imaging applications including intravital visualization of capillaries 
and macrophages, sentinel lymph node mapping, and peptide-mediated multi-color 
cell labeling for real-time imaging of tumor metastasis and tracking of injected bone 
marrow cells in mice. These results demonstrate that fluorescent core-shell silica 
nanoparticles represent a powerful novel imaging tool within the field of 
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I attempted to develop a mouse model of soft tissue sarcoma (STS) associated 
with inactivation of p53 and Rb, tumor suppressor genes. Since p53-deficient mice 
succumb to rapidly progressing lymphomas and germline biallelic inactivation of Rb 
cause embryonic lethality, I used a conditional inactivation of p53 and/or Rb by a 
single subcutaneous injection of adenovirus carrying Cre-recombinase into adult 
genetically modified mice with floxed copies of p53 and/or Rb genes in order to 
induce a development of sarcomas. I characterized induced STS and evaluated their 
cellular origin with a particular attention to mesenchymal stem cells. Next, I focused 
on a development of biomedical tools for future studies of STS origin and 
pathogenesis with recently introduced silica nanoparticles, C dots. Towards 
visualizing sarcoma development, I tested toxicity of C dots in cell culture and in vivo 
and evaluated several possible applications of these particles for future biological and 
biomedical studies. 
In this chapter, I will describe the current status of soft tissue sarcomas 
including their definitions, common genetic alterations, presumed histogenesis and 
treatment. I will describe in detail the mesenchymal origin hypothesis in STS and 
increasing evidence supporting this hypothesis. Additionally, I will outline a current 
mouse model of STS and discuss the advantage of our mouse model induced by an 
inactivation of two major tumor suppressor genes, p53 and Rb, as compared with other 
models. Following these, C dots will be introduced as a new useful biomedical tool for 
a rapidly increasing field of nanobiotechnology. Finally, I will provide my conclusions 
about project and outline future directions.  
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1.1 Soft tissue sarcoma 
Sarcomas are a large heterogeneous group of rare tumors that arise from 
derivates of mesenchymal tissues, which are derived from embryonic mesoderm with 
some contribution of neuroectoderm. They may occur anywhere in the body and at 
any age. Sarcomas include such types as bone sarcoma, Ewing’s sarcoma, peripheral 
primitive neuroectodermal tumors, and soft tissue tumors, which are the most 
frequent. Soft tissues sarcomas (STS) are malignant neoplasms arising from 
nonepithelial and extraskeletal tissues, such as connective tissue, muscles, vessels and 
peripheral nerves. STS are classified on a histogenetic basis according to the adult 
tissue they resemble. Within the various histogenetic categories, soft tissue tumors are 
usually divided into benign and malignant forms. Benign tumors more closely 
resemble normal tissue and have a limited capacity for autonomous growth. They 
exhibit little tendency to invade locally and are characterized by a low rate of local 
recurrence following conservative therapy. On the other hand, malignant tumors, or 
sarcomas, are locally aggressive and are capable of invasion or destructive growth, 
recurrence, and distant metastasis (Enzinger and Weiss, 2001). Currently, more than 
50 histologic groups of STS have been identified, with the most common type being 
undifferentiated high grade pleomorphic sarcoma (UPS), also known as malignant 
fibrous histiocytoma (MFH) in adults and a rhabdomyosarcoma in childhood (Cormier 
and Pollock, 2004). In 2009, new estimated STS diagnosed account for less than 1% 
of all cancers (Jemal et al., 2009). Diagnosis and treatment of STS have been 
challenging due to their rarity and diversity in genetics and phenotypes. 
The etiology and pathogenesis of most STS are still poorly understood. 
Recognized causes include various physical and chemical factors, exposure to ionizing 
radiation, and inherited or acquired immunologic defects. Evaluation of the exact 
cause is often difficult because of the long latent period between the time of exposure 
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and the development of sarcoma, as well as the possible effect of multiple 
environmental and hereditary factors during the induction period.  
Development of a useful, comprehensive histology classification of STS has 
been a relatively slow process. Until recently, the clinical importance of histological 
typing and subtyping of STS was minor, and their treatment depended more on grade, 
stage, and technical considerations in relation to the site. In some case, like 
fibrosarcomas, haemangiopericytomas, and MFH, poorly defined entities had a 
tendency to become diagnostic ‘waste baskets’. The clinical management of these 
tumors was independent of their subclassification. However, with the advance in 
immunohistochemical (IHC) applications and the accumulating knowledge of 
molecular mechanisms of growth and oncogenesis, new treatment strategies are 
gradually becoming possible. The new WHO classification represents a summary of 
recent pathobiological advances and provides a new baseline for a clinical as well as 
laboratory research (Daugaard, 2004). In this classification, the importance of correct 
histotyping has been recognized by the incorporation of IHC into the diagnostic 
criteria, and in many cases cytogenetic data has also been included. For example, in 
the case of MFH, except the myxoid form, it is now considered to be ‘undifferentiated 
pleomorphic sarcomas (UPS)’ based on the absence of their characteristic IHC profile 
and specific cytogenetic aberrations. The myxoid MFH is synonymous with 
myxofibrosarcoma. The term of MFH was first proposed from an observation that 
cultured fibroblast adopted phagocytic qualities resembling histiocytes (Kauffman and 
Stout, 1961; O'Brien and Stout, 1964; Ozzello et al., 1963). However, this diagnostic 
category had brought many questions and considerations from following a careful 
analysis of tumors identified as MFH. The term UPS has remains of questionable 
validity and usefulness as a diagnostic category (Adrien et al., 2009).  
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The management of newly diagnosed sarcomas is complicated. The current 
treatment of sarcomas generally involves surgery in parallel with radiotherapy and 
chemotherapy dependent upon demands. Although surgical excision remains the 
dominant curative therapy, it has a blurry line between unresectable and resectable 
sarcomas. Radiation can be effective treatment to decrease local recurrence of STS. 
However, it is not surprising that many important issues are under debate. Those 
issues concern the relative merits of preoperative versus postoperative radiotherapy 
and a multitude of side effects. Overall, chemotherapy has been relatively 
unsuccessful for treating sarcomas. Use of doxorubicin or ifosfamide remains 
controversial because of the toxicity. Decision-making is more difficult in tumors 
considered high risk. The timing and order of wide local resection, preoperative or 
postoperative radiotherapy, and preoperative or postoperative chemotherapy require a 
multidisiciplinary approach. While advances have been made, the treatment of STS 
still has much room for improvement (Steen and Stephenson, 2008). 
A variety of genetic alterations, which involve three broad types of cancer 
genes; oncogenes, tumor suppressor genes, and caretaker genes, occurs in the 
development of sarcomas. Currently, sarcomas can be separated into two classes by 
genetic analysis: one comprises of tumors that display multiple complex karyotypic 
abnormalities with no specific pattern: the other is composed of tumors that harbor 
relatively simple genetic mutations believed to underlie their pathogenesis. A majority 
of sarcomas including osteosarcoma, UPS, liposarcoma (other than myxoid type), 
angiosarcoma, leiomyosarcoma, fibrosarcoma and skeletal chondrosarcoma belonged 
to the first group. Mutations in oncogenes that are altered by gene amplification, 
translocation, or by a combination of both, may lead to sarcoma development. For 
examples, alterations in KIT and PDGFRA activated by mutations have been observed 
in gastrointestinal stromal tumor (GIST) (Helman and Meltzer, 2003). Translocations 
 5 
 
that fuse the coding sequences of two genes to generate chimeric proteins are 
generally considered a special variety of oncogene, known as fusion oncogenes, of 
which there are numerous examples in sarcomas. Examples are representatively a 
EWS-FLI1 fusion in Ewing sarcoma, a PAX3-FKHR or PAX7-FKHR fusion in 
alveolar rhabdomyosarcomas, a FUS-CHOP or EWS-CHOP fusion in myxoid/round 
cell liposarcomas, and SYT-SSX1 or SYT-SSX2 fusion in synovial sarcomas 
(Enzinger and Weiss, 2001).  
Mutations and deletions in two major tumor suppressor genes, P53 and RB, are 
the most common genetic alteration in human STS (Cormier and Pollock, 2004). 
Mutations of RB, the first tumor suppressor gene, have been found in both inherited 
and sporadic retinoblastomas, which increase the risk of developing sarcomas later in 
life. RB is a regulator of cell proliferation which acts by binding to proteins of the E2F 
family of transcriptional factors that promote transition from the G1 phase to the S 
phase of the cell cycle (Classon and Harlow, 2002). Phosphorylation of the RB 
protein, which is critical for regulation of its function, is mediated by cyclin/cyclin 
dependent kinase (CDK) complexes (Hakem and Mak, 2001). Rb null mice die 
between days 13 and 15 of gestation, with pronounced defects in erythroid, neuronal, 
lens and placental development, as well as skeletal muscle defects (Chau and Wang, 
2003). Although no retinoblastomas develop in mice with targeted disruption of one 
copy of Rb, mice that are heterozygous for Rb show an increased predisposition to 
multiple neuroendocrine neoplasms (Nikitin et al., 1999; Nikitin and Lee, 1996). 
Deletions of RB and its loss-of-function mutations have been extensively documented 
in familial and sporadic retinoblastomas and sporadic osteosarcomas. Loss of RB or 
alterations in RB pathway proteins is frequently observed in various sarcomas (Cohen 
and Geradts, 1997; Sabah et al., 2006; Scambia et al., 2006), including MFH/UPS 
(Chibon et al., 2000).  
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P53 is the most commonly mutated gene in human cancers (Hakem and Mak, 
2001). Inherited P53 mutations are associated with Li-Fraumeni syndrome, which is 
characterized by an increased risk for breast and lung carcinomas, soft tissue 
sarcomas, brain tumors, oesteosarcomas, and leukemia. Binding of MDM2 to P53 
leads to P53 degradation and loss of activity. Once P53 is activated by mitogenic 
signals mediated through deregulated Myc, Ras, or E2F1, or DNA damages that 
involves the regulatory kinase ATM, CHK2, and ATR, P53 regulates multiple 
important cellular pathways such as cell cycle, apoptosis, and differentiation (Hakem 
and Mak, 2001). Additionally, P53 controls the G1 checkpoint of the cell cycle by 
inducing transcription of the cyclin/CDK inhibitor P21, and indirectly the G2 
checkpoint by regulating expression of P21 and the protein 14-3-3σ. Mice bearing null 
mutations of p53 appear normal, but are prone to the spontaneous development of a 
variety of neoplasms, particularly lymphomas, by 6 months of age (Donehower et al., 
1992). Likewise, p53+/- mice are predisposed to carcinogenesis. These animals remain 
cancer-free for the first 9 months but about half go on to develop osteosarcomas, soft 
tissue sarcomas, and lymphomas by 18 months of age. Patients with Li-Faumeni 
syndrome have a 50% increase in the incidence of tumors by the age of 30, which is 
comparable to the tumor incidence in middle-aged (18 month) p53+/- mice.  Mutations 
of p53 has been observed in 30% to 60% of soft tissue sarcomas (Cormier and 
Pollock, 2004; Latres et al., 1994). Additionally, MDM2 amplification has been 
observed as alternative to p53 alteration in many sarcomas (Leach et al., 1993). Since 
mutant p53 protein is expressed in some grade I STS, it has been suggested that its 
expression could have significant translational value as a selection criteria for the 
optimal treatment of sarcoma patients (Hieken and Das Gupta, 1996).   
A cooperative effect on transformation between P53 and RB mutations has 
been reported in several human cancers including sarcomas. Alterations in both P53 
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and RB have been shown in leiomyosarcomas, UPS, and rhabdomyosarcomas 
(Stratton MR, 1990). It is likely that patients with sarcomas carrying both P53 and RB 
alterations have poorer prognosis as compared to those with STS with an alteration in 
one of those genes (Scambia et al., 2006). Based on the fact that human osteosarcomas 
contain mutations in both P53 and RB, an osteosarcoma mouse model was developed 
which is based on  inactivation of p53 and Rb (Berman et al., 2008; Walkley et al., 
2008). Recently, similar cooperation between p53 and Rb inactivation in acceleration 
of osteosarcomas and some STS was observed after expression of Prx1-Cre in the 
early mesenchymal tissues of embryonic limb bud (Lin et al., 2009). However, given 
that the majority of human STS, including UPS develop in late adulthood, this model 
does not represent adequate approach for studies of pathogenesis of adult STS. 
  
1.2 Role of  CXCR4 expression in sarcomas 
Recently, it has been reported that the expression of chemokine receptor 
CXCR4 in human STS is associated with poor prognosis and metastasis (Oda et al., 
2009), particularly in malignant non-round cell tumors such as UPS and 
leiomyosarcoma. Importance of CXCR4-SDF1α signaling for cancer progression and 
metastasis has been reported for a number of human cancers. Human breast cancer 
cells produce high level of functionally active CXCR4, and their distinct in vivo 
distribution was observed in organs representing the main sites of breast cancer 
metastasis (Muller et al., 2001). Furthermore, carcinoma-associated fibroblasts (CAFs) 
located in between breast cancer cells, which have CXCR4, play an central role in 
promoting the growth of tumor cells through secretion of CXCR4 lignad SDF1α. 
CAFs producing SDF1α directly stimulates CXCR4-expressing tumor growth or 
promotes angiogenesis by recruiting endothelial progenitor cells into carcinomas 
(Orimo et al., 2005). Prostate cancer cells expressing CXCR4 were observed 
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migrating across bone marrow endothelial cell monolayers in response to SDF1α 
(Taichman et al., 2002). These observations indicate that CXCR4-SDF1α signaling is 
involved in prostate cancer bone metastasis. Additionally, high expression of CXCR4 
is correlated with poor prognosis in several types of cancer, including pancreatic 
adenocarinoma (Marechal et al., 2009). 
There are very few studies of CXCR4-SDF1α signaling in sarcomas. These 
studies focused on role of CXCR4 in metastasis of rhabdomyosarcomas. It has been 
demonstrated that rhabdomyosarcoma cells have increased metastasis-associated 
properties, such as locomotion, chemotaxis, and adhesion after stimulation by SDF1α 
in cell culture (Libura et al., 2002; Strahm et al., 2008).  
Importantly, p53 has been shown to repress CXCR4 expression (Mehta et al., 
2007). While p53 mutants have failed to repress CXCR4 promoter activity, rescuing 
of p53 deficient breast cancer cells with wild type p53 has reduced CXCR4 
expression. Given frequent occurrence of p53 mutations in STS, these results may 
begin to provide a mechanistic link between p53 and CXCR4 overexpression in 
human STS.  
 
1.3 Cellular origin of soft tissue sarcomas and a mesenchymal stem cell 
The relative rarity of STS and diversity of their histology have hindered the 
identification of the cellular origin of STS and complicated development of rational 
therapeutic approaches. However, because of resemblances to tissues of mesenchymal 
origin, it has been postulated that STSs are derived from mesenchymal stem cells 
(MSC) or mesenchymal progenitor cells committed to specific cell lineages (Mackall 
et al., 2002). The lineage of committed cells belongs to the spectrum of specialized 
mesenchymal tissues including bone, cartilage, muscle, bone marrow, tendon, 
ligament, fat and other connective tissues like dermis (Caplana and Bruder, 2001). 
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MSC were isolated from various human adult tissues, including lung, skin, umbilical 
cord, and amniotic membrane, as a distinct population of primary fibroblast-like cells. 
These fibroblast-like cells can be cultured and are able to differentiate into at least one 
mesenchymal lineage, such as osteoblasts, chondrocytes, and adipocytes ex vivo (Sudo 
et al., 2007). Recently, it has been additionally reported that pericytes located in 
multiple human organs including skeletal muscle, pancreas, adipose tissue, and 
placenta may be a source of MSC (Crisan et al., 2008).  
There is an increasing number of studies that support sarcoma derivation from 
MSC. For example, ex vivo-expanded MSC formed sarcomas in the tail, limb, and 
lung after intravenous injection into irradiated mice (Tolar et al., 2007). In addition, 
long cultured MSC spontaneously transformed and formed complex STS when 
injected subcutaneously into mice (Li et al., 2007). Similarly, sarcomas have arisen 
after MSC/bioscaffold constructs were planted into syngenic or immunodeficient 
recipients (Tasso et al., 2009). In this model, the bioscaffold provided a three-
dimensional support for MSC to aggregate, thus producing the stimulus for triggering 
the process eventually leading to the transformation of surrounding cells and creating 
a surrogate tumor stroma.  
Additional study has shown that MSC of adipose tissue deficient for  p21 and 
p53 form fibrosarcomas with partial adipose differentiation when injected in 
immunodeficient mice either subcutaneously or intrafemorally (Rodriguez et al., 
2009). The development of myxoid liposarcomas and Ewing sarcomas, characterized 
by the unique chromosomal translocation involving fusion proteins, FUS-CHOP and 
EWS-FLI1, respectively, were able to be induced by expression of those fusion 
proteins in MSC (Riggi et al., 2005; Riggi et al., 2006). Like these tumors, alveolar 
rhabdomyosarcoms develop in mice after xenografts of MSC carrying the PAX3-
FKHR fusion proteins, although p53 inactivation often occurs as a cooperative genetic 
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event (Charytonowicz et al., 2009; Ren et al., 2008). Loss of p53 significantly impairs 
the differentiation of muscle progenitor cells and promotes rhabdomyosarcoma 
development in several oncogene-driven mouse tumor model (Stiewe, 2007). 
Furthermore, p53 family members have essential functions in the activation of RB 
during physiological myogenesis. These functions are commonly disabled in 
rhabdomyosarcoma patients, indicating that differentiation control is a critical tumor 
suppressor activity of the p53 family (Cam et al., 2006).  
With poor characteristics and the lack of expression of phenotypic markers in 
undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous 
histiocytoma (MFH), the origin of this sarcoma is still obscure. UPS is described as a 
heterogeneous sarcoma with pleomorphic histiocyte-like and fibroblast-like cells 
frequently arranged in a storiform pattern. These features led to debates about 
histiocyte, fibroblast, and MSC as potential cells of UPS/MFH origin. The derivation 
of histiocyte-like cells in UPS has been a matter of debate. Some initial studies based 
on observations after using human cells and tissues, as well as transplantation models 
have indicated that MFH could arise from the cells of the mononuclear phagocyte 
system, such as histocytes/macrophages (Binder et al., 1992; Hagari and Yumoto, 
1987; Shirasuna et al., 1985; Strauchen and Dimitriu-Bona, 1986; Yamate et al., 1991; 
Yumoto and Morimoto, 1980). However, more recent studied have found no evidence 
of true histiocyte differentiation according to a number of experimental techniques, 
such as cell cultures, immunohistochemistry, and an electron microscopy and stage by 
stage studies of chemical carcinogenesis (Fu et al., 1975; Hoffman and Dickersin, 
1983; Nikitin, 1993; Roholl et al., 1985; Takeya et al., 1995). These studies suggested 
that UPS is a sarcoma of either fibroblastic or primitive mesenchymal origin, which 
manifests both fibroblastic and histiocytic differentiation. For example, human UPS 
cells transplanted into mice developed a sarcoma including fibroblast-like cells from 
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human origin and histiocyte-like cells with positive expressions of mouse specific 
genes (Hatano et al., 1999). Recently, MSC has been favored as a cell of origin of 
UPS/MFH (Gazziola et al., 2003). Some researchers have suggested that UPS may 
have an origin from the perivascular mesenchymal cells that are supposed to have a 
potential for multidirectional differentiation. Monoclonal antibodies against whole cell 
antigens prepared from the established lines of human UPS recognized both 
perivascular MSC and UPS cells. At the same time, macrophages, monocytes and 
other blood cells showed negative immunostaining (Iwasaki et al., 1987). An approach 
using three-pair comparative mRNA profiling of bone marrow derived MSC and 
primary UPS cells showed the striking similarity in the gene expression patterns 
observed between MSC and MFH cells (Gazziola et al., 2003). Furthermore, 
comparative gene expression studies demonstrated similarities between UPS and 
hMSCs in such of stem-cell related properties as expression of DKK, a Wnt inhibitor, 
and absence of Wnt/β-catenin activity. hMSC immortalized with SV40 large T antigen 
were treated with recombinant DKK and injected subcutaneously into nude mice. 
These cells led to UPS development after subcutaneous injection into nude mice 
(Matushansky et al., 2007). 
These results suggest that bone marrow MSC may be the cell of origin of some 
sarcomas, and that aberrant differentiation of MSC by molecular alteration may lead to 
the development of histologically diversified sarcomas. However, these studies were 
based on using MSC isolated from bone marrow cells. Recently, it has been shown 
that, according to cell lineage tracing experiments in irradiation chimeras, STS may 
arise from bone marrow-derived cells (Li et al., 2007). At the same time, no studies 
have yet demonstrated that STS, including UPS, develop from dermal MSC.  
Recently, it has been postulated that cancers, whether solid or hematopoietic, 
contain cancer stem cells (CSC) or tumor-initiating cells that represent a 
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subpopulation of neoplastic cells that may be responsible for cancer initiation and/or 
progression (Cheng et al., 2009). CSC possess stem cell-like properties that include 
the active expression of telomerase and common stem cell genes, the activation of 
antiapoptotic pathways, and an increased ability to migrate and metastasize. 
Furthermore, CSC may remain relatively quiescent and have mechanisms enhancing 
their survival and multi-drug resistance, enabling them to evade traditional cancer 
therapies that target rapidly dividing cells (Cheng et al., 2009; Matoso and Nikitin, 
2008).  
The origin of CSC is still unknown. CSC may originate from mutated stem, 
transit-amplifying, or differentiated cells (Figure 1.1). It is also possible that the 
potential de-differentiation of mutated cells such that these cells acquire stem cell like 
characteristics. This possibility is often used as a potential alternative to any specific 
cell of origin, as it suggests that any cell might become CSC. 
The histological diversity of sarcomas and lack of reliable markers have 
hindered identification of their CSC. Although recently CSC have been identified in 
Ewing's sarcoma (Suva et al., 2009) and embryonal rhabdomyosarcoma (Langenau et 
al., 2007), further studies to better identify them and understand the molecular basis of 
their activity are needed to develop novel therapies targeted against this critical subset 
of cancer cells. Connection between MSC and CSC in various sarcomas remains to be 
determined. Autochthonous mouse models of soft tissue sarcomas that permit the 
study of CSC are relatively underdeveloped. However, imitation of sarcomas by 
conditional gene inactivation, such as a model based on Cre-loxP mediated deletion of 
p53 and activation of K-ras (Kirsch et al., 2007), is a welcome development. The 
generation of mouse models allowing selective targeting of either MSC or more 
differentiated transit-amplifying cells will eventually allow determining the role of 












Figure 1.1. Cancer stem cell hypothesis. Cancer stem cells (CSC, dark green) have 
been defined as a very rare population of cells within tumors that are the only tumor 
cells with the capacity for limitless self-renewal. CSC may derive from mutations in 
stem cells (red), transit-amplifying cells (purple), and possibly even their 







1.4 The status of animal sarcoma modeling 
Animal models have been essential for determining mechanisms of  human 
diseases, such as cancer, and for the design, characterization and evaluation of new 
therapeutic approaches (de Dios, 2002; Frese and Tuveson, 2007).  
The earlier studies of STS histogenesis and pathogenesis were based on 
xenograft sarcoma models or models of sarcomagenesis induced by irradiation or 
chemical compounds. For example, xenografts of human cell lines were commonly 
used for studies of sarcoma progression in immunodeficient mice or nude rats (Maeda 
et al., 2008; Takeya et al., 1995; Tinkey et al., 1999; Zhang et al., 2000). Implantation 
of a 7, 12-dimethylbenz[α]anthracene (DMBA) into the subcutaneous tissue of rats or 
intramuscular injection of benzo[α]pyrene-oil mixture into rats have induced a 
development MFH (Nikitin, 1993; Richter KK, 1999). Furthermore, biomaterials, 
including polyvinyl alcohol (PVA) hydrogel, polyethylene, alphatic polyurethane, 
silicon, titanium, nickel chromium, cobalt-chromium alloy or aluminum oxide, been 
shown to induce MFH after subcutaneous implantation in rats (Kirkpatrick et al., 
2000; Nakamura et al., 2001).  
The manipulation of mouse genome with development of a broad variety of 
genetic tools has enhanced useful features of the mouse models with their original 
benefits, such as the small size and propensity to breed in captivity, relatively short 
lifespan of 3 years, physiological and genetic similarities with humans (Frese and 
Tuveson, 2007; Kile and Hilton, 2005; Rosenthal and Brown, 2007). Genetically 
modified mice provide the most sophisticated tools for modeling of cancer, and allow 
mimicking many pathophysiological and molecular features of human malignancies to 
a far greater extent than other experimental approaches, such as human xenografts and 
chemical and viral carcinogenesis. Importantly, methods for conditional control of 
gene functions, such as the Cre-loxP system, has offered an opportunity for 
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introduction of specific genetic alterations into living mice in temporal and spatial 
manner (Frese and Tuveson, 2007). Cre recombinase was originally isolated from 
bacteriophage P1. Cre recognizes the loxP site consisting of two inverted repeats of 
13-bp flanking an asymmetric spacer region of 8-bp. The Cre enzyme efficiently 
catalyzes reciprocal conservative DNA recombination between pairs of loxP sites. 
Cre-mediated recombination between two directly repeated loxP sites results in 
excision of the DNA between them as a covalently closed circle (Pluck, 1996; Sauer, 
1998). 
About 20% of all sarcomas express recurrent or ‘signature’ genetic events, 
which include single chromosomal translocation (fusion gene) and specific point 
mutations (Riggi et al., 2007; Suva et al., 2007). There are several sarcoma mouse 
models generated transgenetically by expression of these fusion genes. For example, a 
mouse model of myxoid liposarcoma by expressing FUS-CHOP from the elongation 
factor 1α promoter in murine MSC has been developed (Perez-Losada et al., 2000). 
Using a conditional PAX3-FOXO1A knock-in allele targeted to terminally 
differentiating Myf6-expressing skeletal muscle, alveolar rhabdomyosarcoma 
developed at low frequency. Upon crossing these mice with p16INK4A/p19ARF 
deficient or p53 conditional knock-out mice, the frequency of alveolar 
rhabdomyosarco formation was significantly enhanced (Keller et al., 2004; Keller and 
Capecchi, 2005). Similarly, the same sarcoma type was developed using conditional 
knock-in and knock-out techniques that were driven by the chromosomal translocation 
product, Pax3:Fkhr (Keller and Capecchi, 2005). Additionally, a synovial sarcoma 
model has been established recently using conditional expression of SS18-SSX2 in 
myoblast precursors. Beside fusion of genes, introduction of the KIT gene bearing the 
K641E point mutation into the germline has led to the development of both sporadic 
and familial gastrointestinal stromal tumors. Mice in this model show a phenotype that 
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reflects loss of KIT function, including loss of pigmentation, reduced numbers of 
dermal mast cells and sterility. The other GIST model, recently developed by 
expressing KIT bearing a mutation in exon 11 at V558, leads constitutive KIT 
activation in tumors resembled with human GIST (Riggi et al., 2007; Suva et al., 
2007). 
Modeling of sarcomas with complex genotypes, to which the majority of 
pleomorphic STS belong, has been far more challenging. Using Cre-loxP approach, 
high-grade sarcomas with myofibroblastic differentiation were initiated by 
intramuscular delivery of an adenovirus carrying Cre recombinase in mice with 
conditional mutations in K-ras and p53 (Kirsch et al., 2007). However, since Kras 
mutations are not a common genetic alteration in STS (Yoo and Robinson, 1999), this 
model is not well suitable for elucidation of pathogenesis  of common types of STS, 
including UPS. Thus development of a mouse model of adult STS associated with 
inactivation of common alterations, such as p53 and Rb inactivation is of great 
importance.  
 Recently, mice carrying conditional p53 alleles or Rb alleles were generated 
(Figure 1.2). Mice carrying p53 alleles were generated by inserting loxP sites in intron 
1 and intron 10 of the p53 gene using a homologous recombination approach (Jonkers 
et al., 2001, Marino et al., 2000). P53Δ2-10 mice, obtained after crossing with mice 
expressing Cre in the germ-line were showing the same tumor spectrum with 
conventional p53 knockout mice (Jonkers et al., 2001; Marino, 2000; Schwenk et al., 
1995). Mice carrying Rb alleles were generated using targeting vector in which two 
loxP sequences were inserted into the introns surrounding 19 of Rb. Excision of the 
region flanked by the loxP sites results in truncated Rb protein that is functionally 





















Figure 1.2. Structure of floxed alleles of p53 and Rb genes. In the p53 floxed allele, 
loxP sites are inserted into intron 1 and intron 10 of the p53 gene. The Rb floxed allele 
contains loxP sites in the introns surrounding exon 19.   
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These mice represent a valuable tool to develop a mouse model of adult STS 
associated with p53 and Rb inactivation. 
 
1.5 Fluorescent nanoparticles as tools for biomedical imaging 
Applications of nanotechnology in biology and biochemistry are a most rapidly 
developing area of research. In particular, the merging of cancer research and 
nanotechnology, has promised to provide extraordinary opportunities for delivering of 
cancer therapeutic, imaging and sensing system (Ferrari, 2005; Portney and Ozkan, 
2006). For example, several types of nanoparticles have been used as tools for targeted 
delivery of therapeutic agents and cancer imaging. Liposomes have been used for 
drug-delivery, such as doxorubicin, modalities to treat cancers.  Polyethyleneglycol 
(PEG) coated liposomes have showed the longest circulation time and greatest tumor 
accumulation in mice (Ishida et al., 1999). Silica and silicon are emerging as 
interesting candidate materials for injectable nanovectors. These particles have been 
demonstrated to label human leukemia, HepG liver cancer cell, human oral carcinoma, 
and lung carcinoma cells. Advanced forms of silica particles attached to folic acid 
molecules, which bind to folate receptors on the cancer cell surface, have been applied 
for targeted cancer imaging. Metal-based Quantum dots (QDs) or gold nanoparticles 
were recently widely used in cancer imaging (Tan and Zhang, 2005). QDs are the 
most well-known nanoparticles and have been tried in many biological applications 
including labeling cells in vivo or in vitro, mapping lymph nodes or blood vessels, 
visualizing cancers in vivo, and tracking metastatic tumors (Gao et al., 2004; Michalet 
et al., 2005; Voura et al., 2004). Beyond nanoparticles, nanotubes and nanowires are 
promising materials for development of biomolecular nanosensors (Portney and 
Ozkan, 2006). These nanomaterials have been applied as nanoscale field-effect 
transistors, scanning probe microscopy tips, and sensing array elements.  
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QDs are synthesized via colloidal synthesis. Monodisperse CdSe 
nanocrystallites prepared via a high-temperature colloidal growth followed by size 
selective precipitation are overcoated by adding the Zn and S precursors at 
intermediate temperatures (Dabbousi et al., 1997). Since QDs have been introduced as 
new nano-sized fluorophores, they have been widely used in the field of biochemistry 
and biomedical application including cellular labeling and in vivo imaging. QDs have 
overcome handicaps of conventional organic fluorphores with high luminescence, 
stability against photobleaching, and a wide range of fluorescence wavelengths from 
blue to infrared depending on the size. In spite of their strong advantages in imaging, a 
cellular toxicity of QDs has been suggested since they are mainly composed of toxic 
materials like Cd2+, which is a part of a component of CdSe and CdSe/ZnS QDs. The 
toxicity of QDs is well established. For example, the release of Cd2+ ions from the 
surface of CdSe or CdSe/ZnS nanoparticles directly correlates with cytotoxic effects. 
In addition to their cadmium content, the interaction of the nanoparticles surface with 
the cells could influence cell damages (Kirchner et al., 2005).  QDs are insoluble in 
biological solvents because non-polar groups of organic molecules are exposed on the 
surface of QDs. In order to overcome this disadvantage, QDs have been modified with 
water-soluble material like mercaptopropionic acid, silanization, and polymer coating. 
However, it has been reported that cells treated with the water-soluble QDs covered 
with mercapto-undecanoic acid showed decreased cell viability and cell death over a 
certain range of concentration of QDs (Shiohara et al., 2004). Despite of the surface 
modification of QDs, cells get damaged with high concentration of nanoparticles 
(Hoshino et al., 2004; Shiohara et al., 2004).  
Recently Dr. Wiesner at Cornell University has developed highly fluorescent 
monodisperse silica nanoparticles, referred to as C dots, with core-shell architecture 
consisting of organic fluorophores–rich center protected within a siliceous shell (Ow 
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et al., 2005). Covalent incorporation of dye species such as tetramethylrhodamine 
isothiocyanate (TRITC) into the pseudo-solid state environment within the silica 
particle enhances both the brightness and photostability of the dyes, while providing a 
robust, water-soluble vehicle, compared to free TRITC.  Although the brightness per C 
dot is two to three orders of magnitude less than similar hydrodynamic size and 
emission wavelength of QDs, the C dot silica architecture leads to the easy 
modification of surface properties to facilitate targeting or uptake in biological 
systems.  
Application of these new nanoparticles may facilitate our understanding of 
STS formation and monitoring of STS responses to treatment.  For example, such 
studies may lead to intravital identification of cells involved in initiation or 
progression of sarcomagenesis.  
 
1.5 Project overview 
Due to relative rarity, heterogeneity, and variety of subtypes, studies of 
histogenesis and pathogenesis of STS have been challenging thereby leading to 
insufficient development of advanced diagnostic and treatment approaches. This 
situation has been further complicated by the paucity of accurate genetic mouse 
models for the most common type of STS, UPS/MFH.  
STS contain several main characteristics. Mutations and deletions in P53 and 
RB are the most common genetic alterations in human STS. Because of their 
resemblances with tissues of mesenchymal origin, STS may derive from mesenchymal 
stem cells (MSC) or mesenchymal progenitor cells committed to specific cell lineages. 
Several studies has shown that MSC isolated from human or rodent skin or dermal 
tissue differentiated into adipocytes, osteocytes, chondrocytes, neurons, glial cells 
or/and smooth muscle cells (Bartsch et al., 2005; Shi and Cheng, 2003; Toma et al., 
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2001; Toma et al., 2005). Based on these observations, I hypothesized that p53 and Rb 
play critical roles in the STS development and adult dermal mesenchymal stem cells 
represent the preferential target of malignant transformation associated with p53 and 
Rb deficiency. 
Here, I generated a mouse model of STS initiated by Cre-loxP mediated 
conditional inactivation of p53 and Rb tumor suppressors in connective tissue cells of 
the dermis. In chapter 2, the generation of a mouse STS model and identification of 
STS histogenesis will be described in detail. My study demonstrates that according to 
morpho-functional features neoplasms in this model are similar to human STS. Similar 
to their human counterparts, mouse sarcomas overexpress Cxcr4, and its knockdown 
results in reduction of invasive properties of sarcoma cells. By using bone marrow 
transplantation chimeras, I determined that sarcomas did not originate from bone 
marrow cells. Furthermore, to test a possibility that sarcomas originate from resident 
MSC of the dermis I established an enhanced procedure for the isolation of dermal 
MSC by plastic adherence and Sca-1 low expression. I further demonstrated that 
isolated dermal MSC have increased neoplastic potential after inactivation of p53 and 
Rb.  
In order to apply advanced imaging approaches for monitoring mutant 
connective tissue cells in living mouse, I evaluated potential use of core-shell silica 
nanoparticles (C dots). As described in chapter 3, I tested in vivo toxicity and 
biodistribution of C dots after intravenous and subcutaneous administration. After the 
absence of C dot toxicity was established, I was able to demonstrate successful 
labeling of dermal cells including macrophages and blood vessels with C dots and to 
trace cells labeled with different colors into living mice. These approaches will be 
used for future studies of STS pathogenesis. 
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Local mesenchymal stem/progenitor cells are a preferential target for initiation of 
adult soft tissue sarcomas associated with p53 and Rb deficiency 
 
2.1 Abstract 
The cell of origin and pathogenesis of the majority of adult soft tissue 
sarcomas (STS) remains poorly understood. Since mutations in P53 and RB tumor 
suppressor genes are frequent in STS in humans, these genes have been inactivated by 
Cre-loxP mediated recombination in mice with floxed p53 and Rb. Ninety three per 
cent of mice developed spindle cell/pleomorphic sarcomas after a single subcutaneous 
injection of adenovirus carrying Cre-recombinase. Similar to human STS, these 
sarcomas overexpress Cxcr4, which contributes to their invasive properties. By using 
irradiation chimeras generated by transplanting bone marrow cells from mice carrying 
the Rosa26StoploxPLacZ or the Z/EG reporter, as well as floxed p53 and Rb genes, to 
irradiated p53loxP/loxPRbloxP/loxP mice, it has been determined that sarcomas do not 
originate from bone marrow derived cells, such as macrophages, but arise from the 
local resident cells. At the same time, dermal mesenchymal stem cells isolated by 
strict plastic adherence and low levels of Sca-1 expression (Sca-1low, CD31negCD45neg) 
have shown enhanced potential for malignant transformation according to soft agar, 
invasion, and tumorigenicity assays, following conditional inactivation of p53 and Rb. 
Sarcomas formed after transplantation of these cells have features typical for 
undifferentiated high grade pleomorphic sarcomas. Taken together, our studies 
indicate that local Sca-1low dermal mesenchymal stem/progenitor cells are a 





Soft tissues sarcomas (STS) are malignant neoplasms arising from 
nonepithelial and extraskeletal tissues, such as connective tissue, muscles, vessels and 
peripheral nerves. While some sarcomas resemble a specific differentiated tissue (e.g. 
muscle, fat, etc.), many are poorly differentiated and their cell of origin remains a 
topic of debate. Not surprisingly, diagnosis of STS is a difficult task and few reliable 
prognostic criteria, mainly based on sarcoma grade and stage, have been identified 
(Collini et al., 2009; Guillou and Aurias, 2009; Mackall et al., 2002; Weiss and 
Goldblum, 2008).  
 During recent years, a concept has been developed that many STS, particularly 
those without significant presentation of cell lineage-specific markers, may arise from 
mesenchymal stem cells (MSC). The majority of those studies have been based on 
MSC derived from the bone marrow (Li et al., 2009; Matushansky et al., 2007; Tasso 
et al., 2009). The possibility that STS may develop from bone marrow MSC has been 
raised by a report that, according to cell lineage tracing experiments in irradiation 
chimeras, STS arise from bone marrow-derived cells (Li et al., 2007). 
 Genetically, STS can be divided into two groups. One group has a consistent 
set of recurrent genetic alterations, such as translocations (e.g., PAX3-FOXO1A in 
alveolar rhabdomyosarcoma) and specific mutations (e.g. KIT activating mutation in 
gastrointestinal stromal tumors). Another group, which comprises the majority of STS, 
is characterized by complex genomic profiles and frequent presence of mutations in 
tumor suppressor genes P53 and Retinoblastoma 1 (RB) (Collini et al., 2009; Guillou 
and Aurias, 2009; Mackall et al., 2002; Weiss and Goldblum, 2008). Further 
supporting importance of these genes for sarcomagenesis, patients with Li-Fraumeni 
syndrome, which is associated with germline P53 mutations, as well as patients with 
germline RB mutation have a higher frequency of STS (Mackall et al., 2002; Weiss 
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and Goldblum, 2008). In agreement with known cooperation between P53 and RB 
pathways, mutations in both genes are frequent in STS (Stratton et al., 1990). It has 
been recently reported that conditional Cre-loxP mediated inactivation of p53 by 
expression of Osterix-Cre transgene in committed osteoblast progenitors results in 
formation of osteosarcomas, and loss of Rb potentiates osteosarcomagenesis (Berman 
et al., 2008; Walkley et al., 2008). Similar cooperation between p53 and Rb 
inactivation in acceleration of sarcomagenesis was also observed after expression of 
Prx1-Cre transgene in mesenchymal cells of mouse embryonic limbs (Lin et al., 
2009). In addition to predominant osteosarcoma formation, development of poorly 
differentiated STS was also reported in that model. However, given that the majority 
of human STS affect adults (Weiss and Goldblum, 2008), interpretation of this model 
has been somewhat complicated due to expression of Prx1-Cre transgene in the early 
mesenchymal tissues. 
By using conditional activation of K-ras and inactivation of p53 by 
intramuscular injection of adenovirus expressing Cre recombinase (AdCMVCre) into 
adult mice Kirsch et al. (Kirsch et al., 2007) have established a mouse model of adult 
high-grade sarcomas with myofibroblastic differentiation. We have used a similar 
approach for initiation of STS associated with p53 and Rb deficiency by subcutaneous 
AdCMVCre administration and demonstrate that the majority of these neoplasms are 
undifferentiated high grade pleomorphic sarcomas (UPS), also known as malignant 
fibrous histiocytomas (MFH). Notably, similar to their human counterparts, mouse 
sarcomas overexpress Cxcr4, and its knockdown results in reduction of invasive 
properties of sarcoma cells. Based on bone marrow reconstitution experiments we 
have determined that STS have local as opposed to bone marrow origin. Finally, by 
using enhanced purification of dermal MSC we have demonstrated that these cells 
have superior transformation potential and form UPS after p53 and Rb inactivation.   
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2.3 Materials and methods 
Experimental animals  
Mice with floxed copies of p53 and Rb genes were prepared as described previously 
(Jonkers et al., 2001; Marino, 2000). FVB/N mice were used for controls. Reporter 
mice Z/EG (Tg(ACTB-Bgeo/GFP)21Lbe/J; (Novak et al., 2000)), Rosa26StoploxPLacZ 
(B6;129-Gt(ROSA)26Sortm1Sor/J; (Chai et al., 2000; Jiang et al., 2000)), B5/EGFP 
(FVB.Cg-Tg(ACTB-EGPF)B5Nagy/J (Hadjantonakis et al., 1998)) and Rosa26LacZ 
(B6; 129S-Gt(ROSA)26Sor/J; (Soriano, 1999)) were obtained from the Jackson 
Laboratory (Bar Harbor, ME). All experiments were conducted under identical 
conditions, following recommendations of the Institutional Laboratory Animal Use 
and Care Committee of Cornell University.  
 
Genotyping  
p53loxP/loxP and RbloxP/loxP mice were identified by PCR genotyping essentially as 
previously described (Flesken-Nikitin et al., 2003). Mice carrying LacZ were detected 
with PCR primers LACZ5’ (5’ GCG TTG GCA ATT TAA CCG CCA GTC A 3’) and 
LACZ3’ (5’ TCA GCA CCG CAT CAG CAA GTG TAT C 3’) yielding 240-bp DNA 
fragment. Mice carrying EGFP were identified with PCR primers ZEGneo1 (5’ AGA 
GGC TAT TCG GCT ATG ACT G 3’) and ZEGneo2 (5’ TTC GTC CAG ATC ATC 
CTG ATC 3’) yielding 430-bp DNA fragment.  
 
Adenovirus administration 
Recombinant adenoviruses AdCMVLacZ, AdCMVCre, AdCMVeGFP, and 
AdCMVCre-EGFP are modifications of the adenovirus-5 genome, from which the ela 
and elb regions required for viral replication have been deleted and replaced with 
Escherichia coli-derived LacZ, Cre, or enhanced green fluorescent protein (EGFP) 
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adjacent to the CMV immediate early regulatory sequence ((Anderson et al., 2000), 
Gene Transfer Vector Core; University of Iowa, Iowa City, IA). After deep anesthesia 
with intraperitoneal (IP) Avertin (2.5% v/v in 0.85% NaCl; 0.02 ml/g body weight), 
mice were shaved and adenovirus (5×108 pfu/μl in saline) was injected into the 
subcutaneous (SC) tissue of the dorsal area with 21 gauge needle under the control of 
a dissection microscope. The needle was slowly withdrawn to avoid any accidental 
leak of adenovirus. According to experiments with AdCMVEGFP, AdCMVCre and C-
dots (Choi et al., 2007) labeled cells were located in the reticular layer of the dermis 
and in the adjacent loose connective tissue of the hypodermis. Given the continuum of 
both areas, cells of both regions were used in all experiments and indicated as 
"dermal" cells.  
 
Generation of irradiation chimeras 
Six to seven weeks old wild-type FVB/N or p53loxP/loxPRbloxP/loxP mice were irradiated 
at 11 Gy, 2 Gy/min) by using PRIMUS Linear Accelerator (SIEMENS, Malvern, PA) 
or a sealed cesium137 source irradiator Mark 1- 68 (JL Shepherd and Associates, San 
Fernando, CA). According to the preliminary test experiments, irradiation in both 
devices resulted in comparable depletion of bone marrow cells. Within 4 hours after 
irradiation, mice were rescued by tail vein injection of 106 bone marrow cells derived 
from the Z/EG or the Rosa26StoploxPLacZ p53loxP/loxPRBloxP/loxP mice as described in 
(Cui et al., 2002; McDonald et al., 1970). To generate positive control mice, bone 
marrow cells from B5/EGFP or Rosa26LacZ reporter mice were administrated into 
irradiated mice. Fourteen days after bone marrow reconstitution, AdCMVCre was 
administrated subcutaneously into chimeras to induce a sarcoma as described above. 
In addition to tumor collection, blood for PCR genotyping was collected from the 
orbital sinus after anesthesia. 
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 In order to evaluate a proportion of donor bone marrow cells in chimeras, bone 
marrow cells were collected from the femur and the dermis of chimeras rescued by 
bone marrow cells from B5/EGFP reporter mice. Bone marrow cells were stained with 
PerCP-Cy5.5 anti-mouse Gr-1 (eBioscience, Inc., San Diego, CA) for 30 minutes on 
ice and then analyzed by a BD LSRII analyzer (BD Biosciences, Franklin Lakes, NJ). 
All collected data was analyzed by FlowJo software (Tree Star, Inc. Ashland, OR). 
The skin tissues were fixed in 4% paraformaldehyde overnight and embedded in 
paraffin.  
 
Pathological evaluation  
For long-term survival experiments mice were monitored daily for 600 days, until 
becoming moribund or until tumor reached 1 cm in diameter. For short-term 
experiments, mice were killed at 1, 3, 7, and 14 days post-administration of 
adenovirus. Mice were anesthetized with Avertin and subjected to cardiac perfusion at 
90 mm of Hg with phosphate-buffered 4% paraformaldehyde. Tumor, skin, lung, liver, 
and spleen, as well as organs with pathological changes, were examined during 
necropsy and placed into 4% paraformaldehyde for postfixation overnight. For short-
term experiments with EGFP adenoviruses, the entire dorsal skin from the shoulder to 
hip was collected and visualized using fluorescence microscopy. Representative 
specimens were further characterized by microscopic analysis of paraffin sections, cut 
4 μm thick, and stained with hematoxylin and eosin. All neoplasms were classified 
according to current histological classification of mouse (Mohr, 2001) and human 







For avidin-biotin-peroxidase-based (ABC) detection, deparaffinized and rehydrated 
sections were subjected to antigen retrieval by either boiling in 10 mM sodium citrate 
buffer (pH 6.0, 10 min) for antibodies to desmin, procollagen type I, EGFP and 
CXCR4 or trypsin pre-treatment for antibodies to CD31 and F4/80. The antibodies to 
F4/80 (1:200; Serotec, Raleigh, NC), procollagen type I (Y-18; 1:50; Santa Cruz 
Biotechnology, Santa Cruz, CA), CD31 (PECAM-1; 1:100; BD Biosciences), smooth 
muscle actin (1:300; Spring bioscience, Fremont, CA), desmin (1:200; Accurate 
Chemical & Scientific Corporation, Wesbury, NY), CXCR4 antibody (1:200; Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, β-galactosidase (1:500; abcam, Cambridge, 
MA) or EGFP (1:500; NOVUS biologicals, Littleton, CO) were incubated for 1 hour 
at room temperature (RT) with exception of except CD31 used for overnight at 4°C. 
The antibody to α-sarcomeric actin (1:1500; Sigma, St. Louis, MO) was incubated 
using MOM Kit (Vector, Burlingame, CA) for 20 min at RT. Following treatment 
with 0.3% H2O2 in methanol, sections were incubated with biotinylated secondary 
antibodies and ABC complex and visualized using 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) and counterstaining with hematoxylin essentially as 
described previously (Zhou et al., 2006). As a control, primary antibodies were 
replaced with non-immune sera of the same species.  
 For immunostaining of STS array (US Biomax, Inc., Rockville, MD) slides 
were incubated at 60°C for 2 hours according to the manufacturer’s instructions and 
then processed for staining with antibody to CXCR4 as described above. The 
semiquantitative assessment of staining level was performed as follows: -, no 
detectable staining; +, <30% of cells are positive, ++ 30-60% of cells are positive, 
+++, > 60% of cells are positive. 
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 For double immunofluorescence analysis the deparaffinized sections of 4% 
paraformaldehyde-fixed tissue were incubated with rabbit antibodies to EGFP (1:300) 
for 1 hour at 37°C or rabbit antibodies to CXCR4 (1:100) or rat antibodies to F4/80 
(1:100) for 1 hour, RT, followed by Alexa Fluor 488 conjugated donkey anti-rabbit or 
anti-rat secondary antibody (Invitrogen, Carlsbad, CA) for 30 min, RT. Subsequently, 
goat antibodies to procollagen type I (1:50), Iba-1 (1:200; abcam) or rabbit antibodies 
to CXCR4 (1:100) were applied for 1 hour, RT, followed by Alexa Fluor 594 
conjugated donkey anti-goat or anti-rabbit secondary antibody (Invitrogen) was 
incubated with sections.  
 For immunostaining on frozen sections, tissues were frozen in liquid nitrogen 
with Tissue-Tek® (SAKURA®, McGaw Park, IL). Seven µm thick tissue sections 
were placed onto Superfrost plus-coated slides (Fisher Scientific, Pittsburgh, PA) and 
fixed in cold acetone (-20°C) for 10 min. Sections were incubated with primary 
antibody to F4/80 (1:100), Iba-1 (1:200), CD31 (1:100), smooth muscle actin (1:200), 
and procollagen type I (1:50) at RT for 1 hour or to CD31 (1:100) at 4°C for overnight 
followed by secondary antibodies conjugated with Alexa Fluor 594. Counterstaining 
was performed by incubation for 1 minute with DAPI (1 mg/ml of an aqueous solution 
diluted 1:100 in TBS). Slides were mounted with GEL/MOUNTTM (Biomeda corp, 
Foster City, CA) and viewed with a Zeiss LSM 510-META confocal microscope.  
 
Cell culture  
Tissue cultures were maintained using Dulbecco’s modification of Eagle’s medium 
(DMEM; Cellgro®, Mediatech, Inc., Manassas, VA), containing 10% heat inactivated 
Fetal Bovine Serum (FBS; Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 
mM L-glutamine, and 1 mM sodium pyruvate (Cellgro®). Primary fibroblast culture 
was prepared from tail dermis of adult p53loxP/loxPRbloxP/loxP mice. The collected tissue 
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was washed 3 times in 70% EtOH and 3 times in PBS, minced finely, and 
disaggregated with 0.05% trypsin/0.53 mM EDTA (Cellgro®) for 1 hr, 37°C. The 
trypsin was removed by centrifugation and the cells were resuspended in medium. The 
cells were plated in two 6 cm diameter tissue culture dishes. 
 For adenovirus infection adherent or suspension cells were plated at a 
concentration of 105 cells in 3 ml of complete growth medium per well in 6-well 
plates. When cells reached 70% confluence, they were washed twice with PBS and 
AdCMVCre or AdCMVEGFP was added at a concentration of 5x108 pfu/ml in 1 ml of 
serum free growth medium. After incubation for 2 hours at 37°C with 5% CO2, the 
virus containing medium was removed and the cells were washed two times with PBS.  
The cells were given at least 3 days to recover in complete growth medium before use 
in further assays.  
 Cell lines STN1 and STN2 were established from angiosarcoma and UPS, 
respectively, developed in p53loxP/loxPRbloxP/loxP mice after SC AdCMVCre injection. 
FBN1 cell line was established 40 passages after Cre-loxP-mediated deletion of p53 
and Rb in plastic adherent dermal cells. Cultures were maintained at 37ºC and 5% 
CO2, and medium replaced every 3-4 days.  
 
Western blotting 
Cells were lysed in RIPA (25mM Tris, pH8.2, 50 mM NaCl, 0.1% SDS, 0.5% Nonidet 
P-40 and 0.5% deoxycholate) buffer with protease inhibitors as described previously 
(Matoso et al., 2008). Proteins were resolved on SDS-PAGE gels and transferred to 
nitrocellulose via semi-dry transfer (BioRad, Hercules, CA). Immunoblots were 
blocked with 5% milk in TBST for 1 hour and washed three times with fresh TBST. 
CXCR4 antibody (1:200; Santa Cruz Biotechnology, Inc.) was incubated with 
immunoblots for overnight at 4°C followed by HRP-conjugated anti-rabbit antibody (1 
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hour at RT) and detection with SuperSignal West Pico Chemiluminescent Substrate 
(Pierce Biotechnology, Inc., Rockland, IL). 
 
Cxcr4-siRNA transfection 
One day before transfection, cells were plated with 2 ml of growth medium without 
antibiotics in a 6-well plate. Five nmol Cxcr4-siRNA (Accell SMART pool siRNA A-
060184-13~16, CXCR4; Target sequence CGAUCAGUGUGAGUAUAUA, 
GUGGUAAAUUGAAUAAAGC, GCAUCGUGCACAAGUGGAU, or 
GGUUUGACUUAAUUUAUAU) or control-siRNA oligomer (Thermo Scientific, 
Waltham, MA) was diluted in siRNA buffer (Thermo Scientific) to make a 100 μM 
siRNA solution. 7.5 μL of the 100 μM siRNA was combined with 750 μL Accell 
delivery media (Thermo Scientific) and 100 μL of the appropriate delivery mix was 
added to each well containing cells with ~50% of confluence. Cells were incubated at 
37°C in a 5% CO2 incubator for 72 hours until using for an invasion assay.  
 
Isolation of mesenchymal stem cells 
Plastic adherent dermal (PAD) cells were prepared from six to seven weeks old 
p53loxP/loxPRbloxP/loxP male transgenic mice according to a protocol by Wilson et al. 
(Wilson et al., 2002) with modifications. Briefly, euthanized mice were shaved and 
treated with Nair® (Church & Dwight Co., Inc., Princeton, NJ) prior to skin removal. 
Harvested skin was cut into 1 cm2 pieces and incubated for 1 hour at 37ºC in enzyme 
mix A, consisting of 5 U/ml dispase (Sigma) and 3% FBS in PBS. Following this, the 
epidermis was discarded by mechanical dissociation and the remaining tissue was 
incubated overnight at 4ºC in enzyme mix A. Tissue was then incubated for 2 hours at 
37ºC in enzyme mix B, consisting of 1.0 U/ml dispase, 0.13 U/ml collagenase 
(Sigma), 700 U/ml hyaluronidase (Sigma), and 20 U/ml DNAse I (Sigma) in 1xPBS. 
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Both enzyme mix A and B were combined and forced through a 70 µm strainer for a 
single cell suspension. Cells were subsequently plated in complete medium at 5x106 
cells/10 cm plate. PAD cells in passage 1 were detached and suspended in antibody 
staining buffer, consisting of 0.1% bovine serum albumin (BSA; Sigma) in PBS. 
Negative selection was carried out using magnetic Dynabeads® (Invitrogen) with 
CD31 (Platelet Endothelial Cell Adhesion Molecule-1, PECAM-1) and CD45 
(Leukocyte Common Antigen, Ly-5) biotinylated antibodies (BD Biosciences). Cells 
were incubated at 4°C for 30 minutes at a concentration 1 µg of antibodies per 106 
cells, according to the manufacturer’s instructions. Supernatant containing CD31-
/CD45- cells was used for Fluorescence-Activated Cell Sorting (FACS) after 
incubation with fluorescein-conjugated antibodies to Ly-6A/E (Sca-1; BD 
Biosciences) at a concentration of 1 µg of antibodies per 106 cells at 4ºC, in the dark, 
for 30 minutes. Appropriate isotype controls were utilized for accurate gating 
parameters. FACS was conducted using a FACSAriaTM cell sorter (BD Biosciences).  
 
Differentiation assay 
Sorted cells in passage 3 were re-plated onto 6-well plates at a concentration of 5x105 
cells per well in 3 ml of a complete growth medium. When cells were confluent, 
medium was removed and replaced with appropriate differentiation or control 
medium. Control medium consisted of DMEM with 1% FBS in order to reduce non-
specific differentiation. Cells were cultured from 6 to 21 days, depending on the assay 
type, and had medium replaced every 2 days. Adipocyte differentiation medium 
contains 5 µg/ml insulin (Sigma), 1 µM dexamethasone (Sigma), 0.5 mM IBMX 
(Sigma), and 10% FBS in DMEM:F12 (Cellgro®). The cells were maintained for 7 
days, then fixed with 4% paraformaldehyde, stained with 0.21% (w/v) Oil Red O 
(Sigma) in 60% isopropanol for 10 minutes, and washed with tap water. Chondrocytes 
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were maintained in medium consisting of 200 µM L-ascorbic acid 2-phosphate, 100 
nM dexamethasone, 10 ng/ml TGF- β1 (R&D Systems, Minneapolis, MN), 40 µg/ml 
L-proline (Sigma), 1:100 ITS + Premix (BD Biosciences) and 10% FBS in DMEM for 
14 days. Then, cells were fixed in 2.5% glutaraldehyde, 25 mM sodium acetate, and 
0.4 M MgCl2 containing 0.05% (w/v) Alcian Blue (Sigma) for 48 hours and washed in 
steps with 3% acetic acid, 3% acetic acid/25% ethanol, and 3% acetic acid/50% 
ethanol. For the osteocyte differentiation assay, cells were cultured in 300 µM L-
ascorbic acid 2-phosphate (Sigma), 10 nM dexamethasone, 10 mM 
β-glycerophosphate (Sigma), and 10% FBS in DMEM:F12 for 21 days. Then, cells 
were fixed in 70% ice-cold ethanol for 1 hour, stained with 2% (w/v) Alizarin Red 
(Sigma) pH 4.2, for 10 minutes, and rinsed with 1xPBS. Ten random images of each 
well were taken at 20x magnification for quantification.  
 
Soft agar colony formation, invasion and tumorigenicity assays 
All assays were performed as previously described (Corney et al., 2007; Corney et al., 
2010; Zhou et al., 2007). Briefly, for soft agar colony formation, PAD cells in passage 
3 were suspended in an agar mix at 5x105 cells/6 cm plate and incubated at 37ºC and 
5% CO2. Analysis was conducted by comparing the number of colonies present in 
each group after 3 weeks of growth in soft agar. For uniformity, a colony was 
considered to be a group of 4 or more cells. For invasion assay, PAD cells in passage 3 
or tumor cells were placed into MatrigelTM Invasion Chambers (BD Biosciences, 
Franklin Lakes, NJ) at concentration 2.5x104 cells/well. For PAD cells, complete 
medium was added in each chamber. For tumor cells treated with either Cxcr4-siRNA 
or scrambled siRNA, 400 ng of Sdf-1 (R&D Systems, Inc.) in serum-free medium was 
added in lower chamber. The plates were then incubated for 22 hours at 37ºC and 5% 
CO2 and  invasion ability was determined by comparing cell number on the bottom of 
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control and invasion wells, respectively, to the original plated density. For 
tumorigenicity assay, 106 PAD cells in passage 3 were injected subcutaneously into 7-
week-old male SCID/NCr mice (Animal production program, NCI-Frederick, 
Frederick, MD) and monitoring of tumor growth and tumor collection were performed 
as described in section Pathological evaluation.  
 
Statistical analyses 
All statistical analyses were performed with the programs InStat 3.05 and Prism 4.03 
(GraphPad, Inc. San Diego, CA). Survival fractions were calculated using the Kaplan-
Meier method. Survival curves were compared by log rank Mantel-Haenszel tests. 




2.4.1 Conditional inactivation of p53 and Rb in dermal connective tissue cells 
results in formation of soft tissue tumors 
In order to test if inactivation of p53 and/or Rb induces soft tissue sarcomas, 
AdCMVCre was subcutaneously injected into the right lower dorsal quadrant of wild-
type or p53loxP/loxP and/or RbloxP/loxP adult male mice. By 600 days of age, three of 30 
p53loxP/loxP mice (10%) and 2 of 26 RbloxP/loxP mice (8%) developed subcutaneous 
tumors (Figure 2.1 and Table 2.1). At the same time, tumors were formed in 27 of 29 
(93%) p53loxP/loxPRbloxP/loxP mice starting at 116 days post-injection. Following initial 
detection of a small, hard mass on the site of injection, tumors developed rapidly and 
aggressively over a period of 1 to 2 weeks and frequently showed ulceration, necrosis 













Figure 2.1. Induction of soft tissue sarcomas by conditional inactivation of p53 
and/or Rb. (A) Sarcomas are detected as a hard mass under the skin (left, before 
opening the skin, right, after opening the skin) at the site of AdCMVCre (dorsal right 
lower quadrant, arrow) but not AdCMVLacZ injection (dorsal left lower quadrant) of 
p53loxp/loxPRbloxP/loxP mice. (B) Survival of wild-type, p53loxP/loxP, RbloxP/loxP, and 
p53loxP/loxPRbloxP/loxP male mice after a single subcutaneous injection of AdCMVCre. 
Mice were sacrificed when sarcoma diameter reached 10 mm in diameter. All 
remaining mice were euthanized at the day 600 end point. Median survival for 
p53loxP/loxPRbloxP/loxP mice was 370 days. n, number of mice in the experimental group. 
(C) Loss of the p53 and Rb genes in soft tissue tumors according to PCR analysis. 
Lanes 1 and 2: STN1 and STN2 cell lines, respectively. Lanes 3 and 4: cells from 
primary tumors negatively sorted for F4/80 and CD11b and analyzed 1 passage (lane 
3) and directly after sorting (lane 4). 295-, 269-, and 247-bp fragments are diagnostic 
for floxed, excised, and wild-type alleles of the Rb gene, respectively. 316-, 198-, and 
163-bp fragments are diagnostic for floxed, excised, and wild-type alleles of the p53 
gene, respectively. C, controls, S, samples, W, blank control, Wt, wild type DNA, 










Table 2.1. Soft tissue sarcomas induced by a single subcutaneous administration 





























































































*Numbers in parentheses indicate number of mice with neoplasm out of total number 
of mice. 
 






the right lower dorsal quadrant of the same mice. Similarly, no tumors were found in 
wild-type mice injected with AdCMVCre. PCR genotyping of primary cells, as well as 
established cell lines from tumors of p53loxP/loxPRbloxP/loxP mice showed deletion of both 
p53 and Rb.   
 
2.4.2 Characterization of soft tissue sarcomas 
The majority of tumors were high grade pleomorphic sarcomas and contained 
highly variable areas consisting of plump spindle cells intermixed with more 
polygonal or round, frequently giant cells with hyperchromatic irregular nuclei (Figure 
2.2A). Multiple mitotic figures and some apoptotic cells were observed and the stroma 
consisted of delicate collagen fibrils encircling individual cells. Invasion of 
surrounding tissues was commonly observed and pulmonary metastasis were detected 
in 1 of 3 (33%) and 7 of 29 (24%) sarcomas of p53loxP/loxP and p53loxP/loxPRbloxP/loxP 
mice respectively. Few neoplasms had distinct histological features consistent with 
angiosarcoma, histiocytic sarcoma, fibrosarcoma and dermatofibroma (Table 2.1). 
Angiosarcoma, and histiocytic sarcoma, respectively expressed markers of endothelial 
(CD31) and histiocytic (F4/80) differentiation. 
 According to immunohistochemical analysis significant areas of desmin and 
either smooth muscle actin or α-sarcomeric actin were detected in several pleomorphic 
sarcomas which were respectively classified as leiomyosarcoma and 
rhabdomyosarcoma. However, seventy per cent of sarcomas (19 of 27) and 33% (1 of 
30) of p53loxP/loxPRbloxP/loxP and p53loxP/loxP mice, respectively, did not demonstrate any 
significant (over 5 %) differentiation with an exception of procollagen type I, a marker  
of collagen producing cells, such as fibroblasts. Additionally, sarcomas frequently 
contained a significant number of cells expressing macrophage marker F4/80 (Figure 









Figure 2.2. Characterization of soft tissue sarcomas. (A) Pathology of soft tissue 
sarcomas induced by p53 and/or Rb inactivation. Expression (arrows, brown color) of 
F4/80 and procollagen type I (PrC), desmin, smooth muscle actin (SMA), α-
sarcomeric actin (α-SA) and CD31 in undifferentiated high grade pleomorphic 
sarcoma (UPS), leiomyosarcoma (LS), rhabdomyosarcoma (RS) and angiosarcoma 
(AS). Hematoxylin and eosin (left column images), and ABC Elite method with 
hematoxylin counterstaining (right column images). Calibration bar: 50 μm (All large 
images), 20 μm (All insets). (B) Gating of STS cells positive (double pos, 17%) or 
negative (double neg, 6%) for F4/80 (PE) and CD11b (FITC) during FACS based 
isolation. (C) Detection of Cre-loxP mediated deletion of the Rb gene by PCR in 
F4/80+CD11b+ (+) and F4/80-CD11b-(-) cell subpopulations isolated by FACS from 
primary STS. loxP, DNA with floxed gene, S1 and S2 indicate representative 
individual tumor samples. See Figure 1 for description of PCR fragments. 
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macrophage population selected by fluorescence-activated cell sorting with antibodies 
to F4/80  and  CD11b,  contained  only traces of Cre-loxP  mediated deletion of the Rb  
gene (Figure 2.2B and C), likely due to phagocytosis of neoplastic cells and/or 
presence of contaminating neoplastic cells. 
 
2.4.3 CXCR4 overexpression contributes to invasive properties of STS 
It has been reported that the expression of CXCR4 in human STSs is 
associated with poor prognosis and metastasis (Oda et al., 2009), particularly in 
malignant non-round cell tumors such as UPS and leiomyosarcoma. In agreement with 
these observations, we determined high expression of CXCR4 in human UPS (MFH) 
and leiomyosarcoma (Table 2.2). Notably, we observed that expression of CXCR4 
was high in UPS, moderate in fibrosarcoma, and negligible in dermatofibrosarcoma 
protuberans (Figure 2.3A).  
 Consistent with observations in human STS, mouse sarcomas expressed Cxcr4 
according to immunostaining and western blot analyses (Figure 2.3B and C). The 
majority of Cxcr4 expressing cells also expressed procollagen type I but not 
macrophage marker F4/80. Levels of CXCR4 were negligible in primary fibroblast 
cell cultures but increased after inactivation of p53 and Rb. To test if Cxcr4 plays role 
in sarcoma progression, Matrigel invasion assays were performed with STS cell lines 
STN1 and STN2 as well as p53 and Rb deficient fibroblastic cell line FBN1. Cells of 
all lines showed increased invasion after addition of Cxcr4 ligand Sdf-1 (Figure 2.3D). 
At the same time, siRNA-mediated knockdown of Cxcr4 significantly reduced 











Figure 2.3. CXCR4 overexpression contributes to invasive properties of STS. (A) 
CXCR4 expression (brown color) in human undifferentiated high grade sarcoma 
(UPS), fibrosarcoma (FS), dermatofibrosarcoma protuberans (DFSP). Note 
preferential expression of CXCR4 in UPS. ABC Elite method with hematoxylin 
counterstaining. (B) Co-localization (yellow color) of Cxcr4 expression in cells 
containing procollagen type I (PrC) but not F4/80. Double immunofluorescence with 
DAPI counterstaining. (A and B) Calibration bar: 50 μm. (C) Cxcr4 expression in wild 
type (Wt) and p53loxP/loxPRbloxP/loxP fibroblasts 2 (p4/2) and 4 (p6/4) passages after 
exposure to AdCMVCre, and in established cell lines FBN1, STN1 and STN2. (D) 
Effects of Sdf1 (left panel) and siRNA-mediated knockdown of Cxcr4 (right panel) on 

















Table 2.2. Expression of CXCR4 in human soft tissue tumors 
Tumor type 
Frequency of tumors with specific level of staining, %* 
- + ++ +++ 
UPS,*  26.7(4/15) 20(3/15) 46.7(7/15) 6.7(1/15) 
Fibrosarcoma  28.6(2/7) 42.9(3/7) 28.6(2/7) 0(0/7) 
DFSP&  100(5/5) 0(0/5) 0(0/5) 0(0/5) 
Neurofibrosarcoma  50(2/4) 25(1/4) 25(1/4) 0(0/4) 
Liposarcoma  18.8(3/16) 50(8/16) 31.3(5/16) 0(0/16) 
Leiomyosarcoma  18.2(2/11) 18.2(2/11) 45.5(5/11) 18.2(2/11) 
Rhabdomyosarcoma  0(0/1) 100(1/1) 0(0/1) 0(0/1) 
Hemangiosarcoma  0(0/1) 0(0/1) 0(0/1) 100(1/1) 
M. Schwannoma  100(1/1) 0(0/1) 0(0/1) 0(0/1) 
* Numbers in parentheses indicate number of particular tumors with specific level of 
CXCR4 expression out of total number of neoplasm's of the same type.  
& Expression CXCR4 is significantly lower in dermatofibrosarcoma protuberance 
(DFSP) as compared to UPS (Fisher’s exact test P=0.0081) and to leiomyosarcoma 





2.4.4 Connective tissue cells targeted with adenovirus 
To establish which dermal cells were targeted by adenovirus, expression of 
EGFP was detected within 1 to 14 days after subcutaneous injection of adenovirus 
expressing Cre-EGFP (AdCMVCre-EGFP). EGFP expression in subcutaneous tissues 
was strongest at 1 and 3 days post infection. According to cell phenotyping, 39% of 
fibroblasts (procollagen type I+), 44% (F4/80+) or 42% (Iba-1+) of macrophages, 
33% of smooth muscle cells (smooth muscle actin+) and 16% of endothelial cells 
(CD31+) were labeled with AdCMVCre-EGFP (Table 2.3 and Figure 2.4A).  
 To test if adenovirus also infected MSC, this population was isolated from 
dissociated dermal cells by strict plastic adhesion followed by negative selection for 
CD45, a marker for cells of hematopoietic origin, including hematopoietic stem cells, 
and for endothelial cell marker CD31 and positive selection for Sca-1 expression 
(Figure 2.4B). Although all plastic adherent cells had a potential for differentiation 
towards adipogenic and osteogenic differentiation (Rodriguez et al., 2009), our studies 
demonstrated that further selection for Sca-1low fraction results in additional 
enrichment for cells with enhanced ability to form adipocytes, chondrocytes and 
osteocytes (Figure 2.4C). All cell subpopulations of plastic adherent cells were equally 
well infected with AdCMVEGFP (Figure 2.9A).  
 
2.4.5 Local origin of STS  
In order to discriminate between bone marrow and local dermal cell of origin 
of STS, irradiation chimeras reconstituted with donor-derived bone marrow cells 
isolated from mice with reporter transgenes were generated (Figure 2.5).  
 In order to evaluate a proportion of donor bone marrow cells, bone marrow 









Table 2.3. Percentage of EGFP-expressing cells in dermal cell populations 3 days 











38.88±18.77 44.33±14.38 42.28±6.53 32.8±33.37 15.66±26.46 










Figure 2.4. Identification of connective tissue cells infected with AdCMVCre-
EGFP adenovirus. (A) Co-localization (yellow color) of EGFP and fibroblastic 
(procollagen type I, PrC), macrophage (F4/80), smooth muscle (smooth muscle actin, 
SMA) or endothelial (CD31) markers. Calibration bar: 50 μm. (B) Expression of 
CD45, CD31 and Sca 1 in plastic adherent dermal cells (left panel). Sorting gates for 
isolation of Sca-1high, Sca-1low, and Sca-1neg. cell populations after negative selection 
for CD45 and CD31 (right panel). (C) Sca-1low cells have a greater potential for 
differentiation into adipocytes, chondrocytes and osteocytes as compared to Sca-1high 
population (p<0.005). Additionally, Sca-1low cells have greater adipocyte and 
chondrocyte potential as compared to Sca-1neg cells (p<0.005). Values (mean ± SD, 
n=3) represent percent of controls without differentiation medium. All experiments 


































Figure 2.5. Identification of soft tissue sarcoma cellular origin in irradiation 
chimeras. p53loxP/loxPRbloxP/loxP  (p53L/LRbL/L) or wild-type mice were exposed to lethal 
dose (11 Gy) of irradiation, followed by rescue with bone marrow cells derived from 
the Rosa26StoploxPLacZ (Rosa26StopLLacZ) or the Z/EG reporter mice containing 
either wild type or floxed p53 and Rb. Soft tissue sarcomas were induced by the 










Figure 2.6. Assessment of bone marrow rescue in irradiation chimeras. (A) 
Efficiency of reconstitution of bone marrow cells according to co-expression of donor-
derived EGFP and granulocyte/monocyte marker Gr-1 between 1 and 14 days after 
irradiation and transplantation of bone marrow from B5/EGFP mice (lower row). Wt 
and B5/EGFP, Gr-1/EGFP profiles of bone marrow cells from wild- type and 
B5/EGFP mice respectively. (B) Detection of ACTBStoploxPEGFP transgene (430 bp) 
by PCR analysis of blood from chimeras that were transplanted with bone marrow 
cells from the Z/EG reporter mice. 316 bp DNA fragment diagnostic of floxed p53 
was used as internal reference control. (W; water control, C; DNA from a mouse 
carrying the Z/EG reporter, as well as floxed p53 and Rb genes, M; marker). Silver 
staining of acrylamide gels. (C) Co-expression of EGFP and macrophage marker Iba-1 
(arrow) in dermal cells 14 days after irradiation and transplantation of bone marrow 









following irradiation and transplantation of bone marrow cells from B5/EGFP reporter 
mouse.  Reduced  number  of  cells  expressing  Gr-1,  a  marker  for  granulocytes and 
monocytes, and limited EGFP expression was detected at 1 and 3 days after irradiation 
followed  by  immediate  bone  marrow  transplantation  (Figure  2. 6  A).   Both cell 
populations increased by day 7 and were within range normal for B5/EGFP reporter 
mouse. These results were consistent with detection of with EGFP transgene copy 
numbers similar to those in B5/EGFP mouse by multiplex PCR (Figure 2.6B). At the 
same time, 24% of Iba-1+ macrophages (98.5 ± 29, Mean ± SD, out of 410 ± 86.3 
counted) expressed EGFP 14 days post-irradiation (Figure 2.6C).  
 In order to determine if any STS developed from bone marrow, sarcomas were 
initiated by a single subcutaneous injection of AdCMVCre into irradiated 
p53loxP/loxPRbloxP/loxP (n=29) and wild-type mice (n=9) reconstituted with bone marrow 
from mice carrying floxed p53 and Rb as well as Rosa26StoploxPLacZ or Z/EG reporter 
constructs. In these reporter constructs, expression of β-galactosidase or EGFP, 
respectively, is possible only after deletion of a STOP codon flanked by loxP sites. 
Additionally, another group of p53loxP/loxPRbloxP/loxP mice (n=4) was reconstituted with 
bone marrow of mice carrying constitutively expressed EGFP (B5/EGFP) or LacZ 
(Rosa26LacZ) transgene. In parallel with collecting tumors, blood from each chimera 
was collected and genotyped by PCR analysis to confirm the reconstitution with donor 
cells. 
 All chimeric mice with host p53loxP/loxPRbloxP/loxP genotype (n=33) but none of 
wild type (n=9) developed sarcomas independently of the type of donor mouse strain. 
The sarcomas were diagnosed as UPS similar to the majority of sarcomas associated 
with p53 and Rb deficiency. The immunohistochemistry results showed that tumors 
from control chimeras rescued with bone marrow of mice carrying constitutively 











Figure 2.7. Detection of bone-marrow derived cells in soft tissue sarcomas. (A) 
Expression of β-galactosidase (β-gal, arrow) and EGFP (arrow) in sarcomas initiated 
by a single sSC AdCMVCre injection into lethally irradiated p53loxP/loxPRbloxP/loxP mice 
transplanted with bone marrow cells from Rosa26LacZ (upper left panel) and 
B5/EGFP reporter mice (lower left panel), but not in those with Rosa26StoploxPLacZ 
(upper right panel), or a Z/EG (lower right panel) bone marrow cells. ABC Elite 
method with hematoxylin counterstaining. (B) Expression of EGFP, procollagen type I 
(PrC) and  F4/80 markers in sarcomas of p53loxP/loxPRbloxP/loxP irradiation chimeras 
reconstituted with bone marrow cells from a B5/EGFP (left panels) and Z/EG reporter 
mice (right panels). Note co-expression (yellow color) of EGFP and F4/80 in sarcoma 
of mouse reconstituted with B5/EGFP bone marrow. Double immunofluorescence 








cells expressing EGFP or β-galactosidase (Figure 2.7). These cells did not have   
atypical  cytological  features  and  expressed  macrophage  marker  F4/80  but  no 
procollagen type I (Figure 2.7). At the same time, sarcomas developed from chimeras 
that contain bone marrow cells from the Z/EG (n=19) or the Rosa26STOPloxPLacZ  
(n=10) reporter mice did not show any GFP or β-galactosidase expression (Figure 
2.7). Thus none of 38 mice developed STS from bone marrow with floxed p53 and Rb. 
Taken together with complete reconstitution of bone marrow cells and 24% 
reconstitution of dermal macrophage population, these results indicate that STS 
associated with p53 and Rb inactivation are most likely originate from the local 
resident as opposed to bone marrow derived cells, such as macrophages. 
 
2.4.6 MSC have enhanced potential for malignant transformation 
To investigate whether dermal MSC could be a target for malignant 
transformation in our model, these cells were subjected to a series of transformation-
related assays after AdCMVCre-mediated inactivation of p53 and Rb. First, the ability 
of the three plastic adherent dermal cell populations to form colonies in soft agar was 
compared. Interestingly, Sca-1low cells showed an increase in the number of colonies 
when compared to the other 2 plastic adherent dermal cell populations (Figure 2.8A). 
Secondly, invasion ability of transformed plastic adherent dermal cells among Sca-
1neg, Sca-1low, and Sca-1high populations was tested using a Matrigel invasion chamber. 
Sca-1low cells once again exhibited the greatest potential for malignant transformation 
compared to the other 2 plastic adherent dermal cell populations (Figure 2.8A). 
Finally, tumorigenicity of MSC was tested after their subcutaneous transplantation 
into scid mice. Sca-1low cells formed tumors faster (Figure 2.8B). Importantly, tumors 













Figure 2.8. Neoplastic potential of dermal mesenchymal stem cells (MSC) after 
conditional inactivation of p53 and Rb. (A) Compared to Sca-1neg and Sca-1high 
subpopulations, the Sca-1low MSC cells have significantly higher propensity for 
forming colonies in soft agar (A, left panel, mean ± SD, n=3, p<0.0001) and invasion 
in Matrigel chamber (right panel, mean ± SD, n=3, Sca-1low versus Sca-1neg, p=0.002; 
Sca-1low versus Sca-1high, p<0.0001) (B) Accelerated formation of tumors after SC 
transplantation of MSC (the Sca-1low MSC cells, median survival 44 days, n=3) as 
compared to mesenchymal non-stem cells (MnSC, Sca-1neg and Sca-1high cells, median 
survival 74 days, n=6; P=0.0376). (C) Undifferentiated high grade pleomorphic 
sarcoma with mitotic figures (H&E, arrow) and expression of procollagen type I (PrC, 
arrow) formed after MSC implantation. Desmin is detected only in smooth muscle 
cells of blood vessels (arrow). Left panel, Hematoxylin and eosin, right panels, ABC 












p53loxP/loxPRbloxP/loxP mice (Figure 2.8D). These tumors expressed procollagen type I 
but no other diagnostic markers in neoplastic cells, including desmin (Figure 2.8C).  
These results indicate that Sca-1low multipotent dermal stem/progenitor cells 




STS are relatively uncommon neoplasms and constitute less than 1% of all 
cancers, with an estimated 10,660 new STSs diagnoses and 3,820 related deaths in 
2009 (Jemal et al., 2009). However, lack of identifiable precursor lesions and high 
heterogeneity of these neoplasms, as well as incomplete understanding of ontogenesis 
and phenotypical plasticity of normal connective tissue cells represent a continuous 
challenge for diagnosis, which is reflected in continuous shift in STS classifications. 
Therefore, development of mouse models which accurately recapitulate both 
morphological features and frequent genetic alterations of human STS is of critical 
importance. The mouse model of STS reported here addresses this need because 
histology of induced sarcomas is similar to those of human STS. Furthermore, 
mutations in p53 and Rb are the most common genetic alterations occurring in 
sarcomas with complex genotype, such as UPS, fibrosarcoma and leiomyosarcoma.  
 Similarity between human STS and sarcomas in our mouse model was further 
confirmed by observation of expression of CXCR4 which is a receptor of chemokine 
CXCL12 (SDF-1α). It has been previously reported that signaling through CXCR4 
plays an important role in progression of a broad variety of malignancies, including 
breast cancers (Muller et al., 2001), prostate cancers (Taichman et al., 2002), 
malignant melanomas (Muller et al., 2001; Scala et al., 2005), gastric cancer 
(Yasumoto et al., 2006), osteosarcomas (Oda et al., 2006) and rhabdomyosarcomas 
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(Strahm et al., 2008). In agreement with a previous report that expression of CXCR4 is 
associated with poor prognosis of STS (Oda et al., 2009) we observed that expression 
of CXCR4 is significantly higher in high grade sarcomas, such as UPS and 
leiomyosarcomas as compared to low grade dermatofibrosarcoma and fibrosarcoma. 
Furthermore, according to our Matrigel invasion assays, stimulation of Cxcr4 by 
addition of Sdf-1 increased invasion of sarcoma cells, while siRNA-mediated 
knockdown of Cxcr4 significantly reduced their invasion. Taken together, these results 
demonstrate that the CXCR4/SDF-1 axis is an important mediator in sarcoma 
progression. It has been reported that CXCR4 expression is repressed by p53 (Mehta 
et al., 2007). Our observations of increased Cxcr4 expression in fibroblasts after p53 
and Rb inactivation is consistent with that report and indicate that inactivation of p53 
during sarcoma initiation may predetermine some of the advanced metastatic traits. 
 Diagnosis of UPS, also known as malignant fibrous histiocytoma (MFH), is a 
matter of a particular controversy. Given the lack of specific immunohistochemical 
markers and firm diagnostic criteria of this neoplasm, it is not surprising that the 
frequency of UPS/MFH diagnosis ranges from 5% to 70 % (Engellau et al., 2004; 
Guillou and Aurias, 2009; Weiss and Goldblum, 2008). MFH was originally described 
by A. P. Stout and colleagues (Kauffman and Stout, 1961; O'Brien and Stout, 1964; 
Ozzello et al., 1963) as a neoplasm consisting of histiocyte-like and fibroblast-like 
cells. Some initial studies performed on human cells and tissues, as well as in 
transplantation experiments, have supported origin of these sarcomas from bone 
marrow derived cells of the mononuclear phagocyte system, that is 
histiocytes/macrophages (Binder et al., 1992; Hagari and Yumoto, 1987; Ozzello et 
al., 1963; Shirasuna et al., 1985; Strauchen and Dimitriu-Bona, 1986; Yamate et al., 
1991; Yumoto and Morimoto, 1980). However, later observations based on advanced 
ultrastructural and immunohistochemical characterization of neoplastic cells, as well 
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as studies of sequential evaluation of sarcoma formation in rats and mice, favor a view 
that UPS/malignant fibrous histiocytomas originate from fibroblastic or mesenchymal 
precursor/stem cells (Fu et al., 1975; Hoffman and Dickersin, 1983; Mackall et al., 
2002; Nikitin, 1993; Takeya et al., 1995). These studies have also demonstrated that 
UPS/MFH frequently contain a large number of non neoplastic infiltrating 
macrophages (Kato et al., 1990; Roessner et al., 1987; Takeya et al., 1995; Takeya et 
al., 1991). Consistent with those reports we observed that cells expressing macrophage 
markers F4/80 and/or Iba1 do not have neoplastic morphology and lack Cre-loxP 
mediated recombination,  
 Some UPS may represent other STS that exhibit high degree of phenotypical 
plasticity during tumor progression (Brooks, 1986; Dehner, 1988; Fletcher, 1992; 
Hollowood and Fletcher, 1995; Katenkamp, 1988). However, findings of MFH-
specific genomic alterations (Mairal et al., 1999; Mandahl et al., 1989; Meltzer et al., 
1991) and gene expression profiles (Nielsen et al., 2002; Segal et al., 2003) indicate 
that diagnosis of UPS/MFH corresponds to a distinct nosologic entity and may reflect 
development of these neoplasms from MSC. 
 Recent progress in isolation of MSC and their potential use in therapeutic 
approaches (Mata et al., 2002; Toma et al., 2001) have renewed interest in assessment 
of transformation potential of these cells. By using human bone marrow MSC 
Matushansky et al. (Matushansky et al., 2007) demonstrated that expression pattern of 
these cells correlates with that of UPS/MFH. Furthermore, they demonstrated that 
MSC immortalized with SV-40 large T antigen recapitulated UPS/MFH morphology 
after subcutaneous transplantation into nude mice. Consistently, formation of UPS was 
reported after transplantation of bone marrow derived mouse MSC treated with 2-
methylcholanthrene (Li et al., 2009). Intriguingly, it has been reported that according 
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to cell lineage tracing experiments in irradiation chimeras, spontaneous fibrosarcomas 
arise from bone marrow-derived cells in the mouse (Li et al., 2007).  
 To evaluate a possibility of bone marrow origin of STS in our model, we have 
performed irradiation chimera experiments in which donor and recipient cells carried 
floxed copies of p53 and Rb. Given 24% reconstitution of dermal macrophage 
population in irradiation chimeras, 70% frequency of UPS in our model and near equal 
infectivity of macrophages and fibroblasts by adenovirus, one would expect that 
sarcomas in 6 to 7 mice could arise from macrophages. However, none of 38 mice 
developed STS from bone marrow with floxed p53 and Rb. These results provide the 
direct experimental evidence that UPS/MFH do not arise from macrophages and 
indicate that initiation of sarcomas from bone marrow derived cells is unlikely.  
 To test if STS may preferentially arise from local resident MSC following p53 
and Rb inactivation we have isolated dermal mesenchymal stem/progenitors cells 
based on their adherence to plastic and expression of Sca-1 marker. Current methods 
for dissociating and isolating cell populations from the dermal are quite variable 
(Fernandes et al., 2004; Gawronska-Kozak, 2004; Rim et al., 2005; Shi and Cheng, 
2003; Toma et al., 2001; Wilson et al., 2002) and different isolation techniques lead to 
enrichment of prospective stem cells with markedly differing characteristics. For 
example, skin-derived precursor cells which form spherical aggregates are capable of 
differentiating into multiple lineages, including cells of the nervous system and 
mesoderm (Fernandes et al., 2004; Toma et al., 2001). At the same time, plastic 
adherent cells of the dermis have proven to be capable of differentiating along classic 
mesenchymal lineages (Gawronska-Kozak, 2004; Rim et al., 2005; Shi and Cheng, 
2003). 
We concentrated on the plastic adherent dermal (PAD) cells for several reasons.  














Figure 2.9. EGFP and Sca-1 expression in one week cultured murine dermal cells 
after adenovirus-induced EGFP expression. Sca-1 expression (Y-axis) and EGFP 
expression (X-axis) was measured by flow cytometry for both plastic adherent (A) and 
suspension cells (B).   
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their suspension counterparts (Figure 2.9). Since our model is based on adenovirus 
delivery of Cre-recombinase, we can assume that PAD cells in p53loxP/loxPRbloxP/loxP 
mice are more readily infected by AdCMVCre and, therefore, are preferentially 
transformed by Cre-loxP-mediated gene inactivation. Additionally, our soft tissue 
sarcoma model does not display any tumors of neuronal origin, but does result in the 
formation of many tumors of mesenchymal origin. Shi, et al. (Shi and Cheng, 2003) 
has  shown  that  strict  selection for  plastic  adherence, within the population  of  cells 
isolated from the rodent dermis, will enrich for multipotent dermal cells. Similar 
observations have been reported for MSC derived from adipose tissue (Rodriguez et 
al., 2009).  
 We decided to further purify MSC population by using Sca-1 (Ly-6A/E) 
expression in combination with negative selection for CD45 and CD31. Sca-1 has 
been shown to be an effective marker for stem cells in many different tissues, 
including MSC (Meirelles Lda and Nardi, 2003; Oh et al., 2004; Sun et al., 2003; 
Welm et al., 2002; Xin et al., 2005). Interestingly, in our experiments the Sca-1low 
population was enriched for multipotent cells. It was reported that Sca-1low population 
was more enriched for stem cells than the expected Sca-1high population in the 
mammary epithelial cells (Stingl et al., 2006) and low levels of positive staining for 
Sca-1 were detected in spermatogonial stem cells (Guan et al., 2006). Similar to these 
observations we also found that prolonged culturing of cells, prior to staining and 
FACS, induced expression of Sca-1 (Curtis and Nikitin, unpublished observations). 
Therefore, it is quite possible that the culture step necessary to select for plastic 
adherence upregulated Sca-1 expression in the PAD cells, throwing off the Sca-1 
expression levels that would be expected based on the majority of studies that sort 
cells prior to any culturing (Kim et al., 2005; Xin et al., 2005). 
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 By using isolated dermal MSC enriched for Sca-1low fraction we were able to 
demonstrate their increased transformation potential, as comported to more 
differentiated connective tissue cells of the dermis, after inactivation of p53 and Rb. 
Interestingly, transformation of dermal MSC resulted in formation of UPS, consistent 
with previous reports which used bone marrow MSC (Li et al., 2009; Matushansky et 
al., 2007). At the same time, Rodriguez et al. (Rodriguez et al., 2009) reported 
formation of fibrosarcomas with areas of adipose tissue differentiation after 
subcutaneous injection of MSC derived from adipose tissue of p21-/- p53-/- mice into 
immunodeficient mice. These variations in tumor type may reflect either different 
differentiation potential of MSC derived from different locations, or gene-dependent 
differentiation potential.  
 Recent observations indicate that p53 and Rb tumor suppressors have 
important functions in stem cells. p53 has been shown to mediate the onset of 
senescence of endothelial progenitor cells, to negatively regulate proliferation and 
survival of neural stem cells, to induce differentiation of embryonic stem cells and to 
control efficiency of induced pluripotent stem cell generation (Feng et al., 2009; Stingl 
and Caldas, 2007; Zhao et al., 2008). Rb and its pathway are involved in control of 
stem cell cycle progression, senescence and tissue homeostasis (Galderisi et al., 2006). 
It has been reported that fibroblasts lacking Rb form spheres and become cancer stem 
cells (Liu et al., 2009). Notably, p16/Rb and ARF/p53 pathways are extensively 
connected and may be coordinately regulated by Bmi-1, which is required for 
maintenance and self-renewal of hematopoietic and neural stem and progenitor cells 
(Valk-Lingbeek et al., 2004). Consistently it has been demonstrated that combined p53 
and Rb deficiency results in prostate cancer arising from the prostate stem cell 
compartment (Zhou et al., 2007). Further studies of established STS model will 
address the specific molecular and cellular mechanisms responsible for cooperation of 
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p53 and Rb in control of MSC and their malignant transformation. It also remains to 
be addressed if sarcomas with distinct differentiation features, such as 
leiomyosarcoma and angiosarcoma, originate from MSC or more committed 
progenitor cells which are less prone to transformation following p53 and Rb 
inactivation. It is of interest that according to comparative genomic hybridization 
studies, UPS/MFH share similarities with leiomyosarcomas (Derre et al., 2001; Segal 
et al., 2003), consistent with frequent observations of areas of smooth muscle 
differentiation in UPS, including our model. 
In conclusion, we have established a genetically engineered mouse model of 
the STS by temporally and spatially controlled p53 and Rb inactivation in connective 
tissue cells of the dermis. We have also demonstrated that STS develop locally, most 
likely from MSC. This mouse model of STS will serve as a valuable basis for future 
studies of STS pathogenesis, particularly of those for sarcomas with complex 
genotypes. This model also provides new opportunities for exploration of targeted 
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Core-shell silica nanoparticles as fluorescent labels for nanomedicine 
 
3.1 Abstract 
Progress in biomedical imaging depends on the development of probes which 
combine low toxicity with high sensitivity, resolution and stability. Towards that end, 
a new class of highly fluorescent core-shell silica nanoparticles with narrow size 
distributions and enhanced photostability, known as C dots, provide an appealing 
alternative to quantum dots. Here C dots are evaluated with a particular emphasis on in 
vivo applications in cancer biology. It is established that C dots are non-toxic at 
biologically-relevant concentrations and can be used in a broad range of imaging 
applications including intravital visualization of capillaries and macrophages, sentinel 
lymph node mapping, and peptide-mediated multi-color cell labeling for real-time 
imaging of tumor metastasis and tracking of injected bone marrow cells in mice. 
These results demonstrate that fluorescent core-shell silica nanoparticles represent a 
powerful novel imaging tool within the emerging field of nanomedicine. 
 
3.2 Introduction 
Advances in biomedical imaging are expected to improve disease detection 
and staging, facilitate treatment selection and monitoring, accelerate our understanding 
of disease pathogenesis and, together with the development of more selective and 
higher-affinity targeted diagnostic and therapeutic agents, lead to the transformation of 
general clinical practice towards personalized medicine. Among current challenges for 
effective translation of newly developing biomedical imaging technologies into 
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clinical settings is identification of the most promising versatile, biocompatible, and 
non-toxic optical probes. In recent years, a variety of nanomaterials including quantum 
dots (QDs`; Alivisatos et al., 2005; Kim et al., 2004; Larson et al., 2003; Medintz et 
al., 2005; Michalet et al., 2005; Stroh et al., 2005), metal nanoshells (Hirsch et al., 
2003), gold and functional silica nanoparticles (Burns et al., 2006a) have begun to 
show their utility in imaging applications promising to realize the tremendous 
scientific and technological potential of nanobiotechnology (Ferrari, 2005; Guan et al., 
2006; Santra et al., 2005a). 
 Currently, the most prominent class of fluorescent nanoprobes in biological 
imaging is QDs. They are characterized by outstanding photostability and brightness 
and have been used for a variety of biomedical applications, such as circulatory 
system imaging, sentinel lymph node mapping, cellular imaging and in vivo cell 
tracking (Akerman et al., 2002; Albini, 1998; Ballou et al., 2004; Gao et al., 2005; 
Kim et al., 2004; Portney and Ozkan, 2006; Shiohara et al., 2004; Stroh et al., 2005; 
Voura et al., 2004). 
 Although QDs offer a number of potential benefits, several properties limit 
their widespread application. There are considerable concerns about QD disposal and 
the toxic heavy metals within the QD core (i.e., cadmium, lead) which can leach into 
solution and cause harm to both cells in culture and animals (Derfus et al., 2004; 
Kirchner et al., 2005; Shiohara et al., 2004). Further, the lack of detailed toxicological 
information on the potential side effects of in vivo QD usage raises the question of 
whether or not these nanoparticles are appropriate for use in biological, and, 
particularly, clinical applications (Alivisatos et al., 2005; Oberdorster et al., 2005). 
Quantum dots are natively incompatible with water, and must be coated with a 
polymer to allow for use in aqueous and biological settings, thus introducing a second 
foreign material into cells, tissue or living organisms (Nagasaki, 2004). Furthermore, 
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single colloidal quantum dots emit intermittently due, in part, to uncontrolled surface 
states, decreasing their usefulness in single particle tracking within live cells or 
intracellular fluids (Neuhauser, 2000).  
 Organic and metallorganic dye molecules have long been used for labeling 
biological samples to increase contrast in both optical and fluorescent analyses 
(Lakowicz, 2006). For fluorescent analyses, emitters are available in colors spanning 
the spectrum from ultraviolet to near-infrared wavelengths (300-900 nm). Although 
there are a wide variety of organic fluorophores available, individual dye molecules 
may suffer from limited brightness (low absorption cross-section and/or low quantum 
yield), environment dependent quenching and photobleaching (Wang et al., 2006). 
 Recent work has shown that the properties of organic fluorophores can be 
improved by covalently integrating them into the core of a core-shell silica 
nanoparticle (Figure 3.1a), (Burns et al., 2006a; Ow et al., 2005). These particles, 
referred to as C dots, can be synthesized with hydrodynamic radii down to 10-15 nm 
as shown by Transmission Electron Microscopy (Figure 3.1b). Covalent incorporation 
of dye species such as tetramethylrhodamine isothiocyanate (TRITC, Figure 3.1a) into 
the pseudo-solid state environment within the silica particle enhances both the 
brightness and photostability of the dyes, while providing a robust, water-soluble 
vehicle. As previously reported (Ow et al., 2005), the brightness per C dot is more 
than an order of magnitude greater than that of the constituent dye, creating a probe 
with a per-particle brightness within a factor of two to three of QDs of similar 
hydrodynamic size and emission wavelength. As well, by integrating multiple 
independent emitters into a single particle, the particles are less prone to stochastic 
blinking, facilitating sustained imaging of the particles. Under excitation saturation 


















Figure 3.1. C dot core-shell fluorescent silica nanoparticles, shown in schematic 
form (a) with the covalently bound TRITC dye within the particle core, (b)  Scanning 
Electron Micrographs of 30 nm diameter C  dot particles. Scale bar 50 nm. This image 
was kindly provided by Dr. Ulrich Wiesner and Andrew A. Burns. 
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individual fluorophores it contains) per particle fluorescence decay time than a single 
fluorophore.  This makes them particularly useful for particle tracking experiments 
where collecting the maximum number of photons per particle per unit time is critical. 
Furthermore, this architecture is readily surface-functionalized to facilitate targeting or 
uptake in biological systems (Ow et al., 2005). Finally, the sol-gel synthesis (Brinker 
and Scherer, 1990) can be tailored to create particles with narrow particle size 
distributions and diameters from tens of nanometers up to microns, facilitating size-
selective analyses (Ow et al., 2005). 
 Perhaps the most promising characteristic of C dots is that because they are 
composed primarily of silica, they are expected to be biologically inert and thus 
potentially non-toxic for research and biomedical applications. In this study, we 
evaluate biodistribution and toxicity of these particles and investigate their biomedical 
utility in a series of in vivo experiments.  
 
4.3 Materials and Methods 
Animals 
Female ICR mice, 7-8 weeks, were purchased from Taconic (Hudson, NY) for the 
biodistribution and toxicity evaluation. Male SCID/NCr (BALB/C background), 6 
weeks, were obtained from the National Cancer Institute (Bethesda, MD) for all other 
experiments. Six to ten weeks old FVB/N mice (inbred) or transgenic mice that carry 
GFP driven by chicken β-actin promoter (FVB.Cg-Tg(ACTB-EGFP)B5Nagy/J; Strain 
003516; The Jackson Laboratory, Bar Harbor, ME) were used for bone marrow 
collection. All experiments were conducted under identical conditions, following 
recommendations of the Institutional Laboratory Animal Care and Use Committee of 
Cornell University.  
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C Dot Synthesis  
Thirty nanometer diameter C dot particles were prepared based on the synthesis 
reported elsewhere (Herz et al., 2006). Briefly, an organic dye (Tetramethylrhodamine 
isothiocyanate or Oregon Green 488 isothiocyanate (TRITC or OG488) Invitrogen, 
Inc.) was dissolved in degassed ethanol (4.57 mM) and conjugated to 3-
aminopropyltriethoxysilane (0.228 M) through the isothiocyanate group. This product 
is reacted with a pure silica precursor (tetraethoxysilane, TEOS, SigmaAldrich, Inc.) 
in the presence of deionized water (1.24 M) and ammonia (0.855 M) as a catalyst and 
allowed to react overnight to form dye-rich core particles. These cores are then coated 
with further TEOS (0.105M) added dropwise over the course of six hours to form the 
outer shell of the particle. The core-shell particles are allowed to react for a further 24 
hours are then dialyzed (Pierce, 3,500 MWCO membrane) to 18.2 MΩ/cm deionized 
water and analyzed to determine size, concentration and photophysical properties (Ow 
et al., 2005).  
 
Biodistribution and Toxicity Experiments  
Thirty nanometer diameter particles were injected intravenously at 3.3 x 10-7 or 3.3 x 
10-8 M in 200 µl of deionized water via the tail vein of mice anaesthetized with 
Avertin (2.5% v/v in 0.85% NaCl; 0.02 ml/g body weight). For each concentration, at 
least 3 mice were collected at one, three, seven, twenty-one and sixty days post-
injection. As a control, mice were injected with distilled water and collected over the 
same time schedule. Mice were observed daily and subjected to careful pathological 
evaluation at the time of necropsy. Brain, thymus, lung, liver, kidney, adrenal gland, 
ovary, spleen, pancreas, intestine, heart, thigh muscle, and skin were fixed in 
phosphate-buffered 4% paraformaldehyde and representative specimens were further 
characterized by microscopic analysis of four micron thick paraffin sections stained 
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with hematoxylin and eosin following standard practices of toxicologic pathology 
assessment (Gad, 2007). For evaluation of C dot distribution sections were 
counterstained with nuclear stain DAPI. Quantitative assessment of fluorescence was 
performed by using custom image analysis software written using the IDL image 
analysis platform (Research Systems Incorporated, Boulder CO). C Dots (and cell 
nuclei) were located by threshholding the blue (and red) channels using the median 
image value plus five (two) times the image standard deviation. Non-zero regions are 
eroded, dilated and then enumerated. Each region of fluorescence in the C Dot channel 
is assigned to the particular nucleus to which it is closest. After collection of at least 5 
images for each specimen, all data were expressed as a mean ± standard deviation.  
 
Immunohistochemistry  
Deparaffinized sections were exposed to 0.02% trypsin (0.05 M Tris-HCl, pH 7.8, 
with 1% calcium chloride, 30 min, 37°C) for antigen retrieval. After Avidin/Biotin 
blocking, samples were incubated with F4/80 antibodies (AbD Serotec, Raleigh, NC) 
for one hour at room temperature and subsequently treated with 0.3% H2O2 in 
methanol. Following incubation with the secondary biotinylated goat anti-rat 
antibodies (Vector Labs Inc., Burlingame, CA, 1:100, 30 min, room temperature) and 
Fluorescein Avidin D (Vector Labs; 3 µg/ml, 30 min, room temperature) the samples 
were counterstained with DAPI. Samples were mounted with GEL/MOUNTTM 
(Biomeda Corp. Foster City, CA), sealed with Clarion Mounting Medium (Biomeda 






In vivo capillary and macrophage labeling  
Mice were prepared for imaging as previously described (Flesken-Nikitin et al., 2005). 
Briefly, mice were anesthetized with 3.5 % Isoflurane and placed on a heating pad 
throughout the experiment. Fur was removed by shaving and Nair® application. 200 
µl of 0.33 µM particles were injected into the tail vein for endothelial blood vessel 
labeling and intradermally for macrophage labeling. The mice were maintained at 1.5 
% Isoflurane for anesthesia and were imaged 1.5 hours after particle injection on a 
multiphoton microscope (Flesken-Nikitin et al., 2005). During imaging, the dorsal 
skin was immobilized to isolate the imaging area from body motion to facilitate high-
resolution imaging.  
 
Sentinel lymph node identification  
Forty µl of 0.4 % trypan blue was injected intradermally in the right paw of an 
anaesthetized mouse. After five minutes, the skin was opened and the lymph node 
located. 70 µl of 0.33 µM C dots were injected intradermally at the same site on the 
paw. The lymph node was imaged by brightfield and fluorescence on an Olympus 
OV100 whole-mouse imaging system (Olympus America Inc., Melville, NY). 
 
C Dot - TAT peptide conjugation  
Oligopeptides of the active region of the TAT protein (residues 48-57) were purchased 
from Sigma-Genosys (The Woodlands, Texas, USA) with a cysteine residue at the C-
terminus. To create the peptide-particle conjugates, 3-aminopropyltriethoxysilane 
(Gelest Inc., Morrisville, PA, USA) was reacted with N-(γ-
maleimidobutryloxy)succinimide ester (GMBS, Pierce Inc, Rockford, IL, USA) in a 
1:1.5 ratio in DMSO to yield a maleimide-silane. This product was reacted overnight 
onto the C dot surface in basic ethanol (0.1M NH4OH). The maleimide-functionalized 
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particles were then reacted with a 100 times excess of TAT48-57 in ethanol to yield 
peptide-functionalized particles. Finally, the particles were dialyzed overnight to 
deionized water to remove unreacted peptide and ethanol and filtered through a sterile 
0.22 μm PTFE filter. 
 
Establishment of PCN2 and PCN2-EGFP prostate cancer cell lines  
Cell line PCN2 was established from prostate carcinoma of 241-day-old PB-Cre4, 
p53loxP/loxPRbloxP/loxP mouse (Zhou et al., 2006). PCN2 tumor cells were cultured in 
DMEM containing 10% FBS at 37°C in a humidified incubator with 5% CO2. To 
prepare PCN2-EGFP cells, PCN2 cells were infected with the pLEGFP-N1 retroviral 
vector from Clontech (Palo Alto, CA) to introduce EGFP to the cells. Viral 
supernatant containing EGFP was generated by packaging cell line EcoPack2-293 
(Clontech) according to manufacturer’s protocols. 1×105 PCN2 cells were exposed to 
viral supernatant containing EGFP in a 6 cm dish at a multiplicity of infection of 1:1 
in the presence of 8 µg/ml polybrene (Sigma, St. Louis, MO) for 24 hours. 
Subsequently, the viral supernatant was replaced with fresh medium. After further 
incubation for 24 hours, infected PCN2 cells were selected with 600 µg/ml G418 for 2 
weeks and EGFP positive cells (PCN2-EGFP) were then sorted by FACS.  
 
C dot labeling in cell culture 
1x106 PCN2 cells were incubated with 1.66 picomol of either nascent or TAT-
conjugated 30 nm C dots for two hours, washed three times with PBS, plated on slides 
and incubated overnight. The following day, the cells were incubated with a lipophilic 
fluorescent probe (DiO-C16 Molecular Probes, Eugene, OR) for plasma membrane 
staining, washed with PBS, counterstained with DAPI in some experiments, mounted 
as above on a Leica TCX-SP2 confocal microscope equipped with a 100x oil 1.40 NA 
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objective with separate excitation for the C dots and DiO-C16 (543 nm and 488 nm, 
respectively).  
 
Isolation and labeling of bone marrow cells with TAT peptide-conjugated particles 
Femoral and tibial bone marrow cells were collected from six to ten week old FVB/N 
or FVB.Cg-Tg(ACTB-EGFP)B5Nagy/J mice by flushing excised and cut leg bones 
with washing medium (DMEM including 2% FBS). The collected cells were washed 
twice and filtered through a 70 µm nylon filter (BD biosciences, San Jose, CA) to 
remove non-cellular material. Isolated bone marrow cells were incubated with TAT 
conjugated C dots for two hours at 1x105 particles/cell. After incubation and washing, 
the cells were injected via the tail vein into FVB/N mice irradiated with a lethal dose 
(11 Gy) of X-rays to ensure removal of their own bone marrow cells. The mice were 
sacrificed by cervical dislocation 24 hours post-injection and tissue sections were 
analyzed as above. 
 
Tracking metastatic and/or bone marrow cells  
106 PCN2-EGFP cells were labeled with TAT-C dots as described for cell culture 
experiments but without labeling with DiO-C16 or DAPI. Following incubation with 
TAT-C dots for two hours and PBS washing cells were injected via the tail vein. For 
simultaneous tracking of two types of cells labeled with different color C dots, a 
mixture of PCN cells, 5x105 cells, labeled with Oregon Green 488-based C dots 
(green) and bone marrow cells, 5x105 cells, labeled with TRITC-based C dots (red) 
was injected into mice intravenously. The lung was collected 5 hours post-injection 




Statistical analyses  
All statistical analyses in this study were done with InStat 3.06 and Prism 4.03 
software (GraphPad, Inc., San Diego, CA). Means were compared by estimation of the 
two-tailed P with Mann-Whitney test. Statistical assessment of multiple samples was 
performed by one way ANOVA and linear regression as necessary. 
 
4.4 Results 
Before investigating biomedical applications of the C dots, we first examined 
the biodistribution and potential toxicity of C Dots in a mouse model system. No 
abnormal clinical signs were evident in mice exposed to tetramethylrhodamine 
(TRITC) dye-based 30 nm diameter core-shell C dots even at the highest 
technologically possible concentration of 0.33 µM administered in 200 µl of deionized 
water by tail-vein injection. The mice behaved normally throughout the experiment 
and showed no pathological alterations in any of the assessed tissues and organs. 
 Analysis of tissue samples revealed that the C dots were predominantly 
localized in the spleen, liver and lung (Figure 3.2a, b, 3.3, and 3.4) following their 
initial appearance in blood vessels throughout the body (Figure 3.5). The particles 
were mainly localized in the cells of the mononuclear phagocyte system such as F4/80 
positive Kupffer cells in the liver (Figure 3.2d). The distribution pattern of C dots in 
the lung, liver and spleen was found to be time and concentration dependent as 
measured by a decrease in the number of cells with C dot fluorescence over time 
(Figure 3.2c, 3.3, and 3.4). At concentration 0.33 μM cells with TRITC-C dots became 
almost undetectable in the liver between 21 and 60 days post-injection (Figure 3.2c 
and 3.4). In order to confirm that the observed disappearance of particles was not due 
to the loss of their fluorescence intensity, we measured the emission of C dots 

















Figure 3.2. Biodistribution of C dots following tail vein injection. TRITC-C dots 
were found to localize predominantly in the spleen (a) and liver (b) with peak levels of 
particle fluorescence (red) occurring within the first week of intravenous injection 
(DAPI counterstain). Hematoxylin and Eosin stained parallel sections of spleen and 
liver show no pathological changes. The number of fluorescent cells (mean ± standard 
deviation) in the liver was monitored over time (c), showing that the C dots were 
almost cleared from over the course of approximately 60 days (red; 0.3 µM, blue; 0.03 
µM 30 nm C dots). (d) Localization of the C dots within F4/80-positive Kupffer cells 


















Figure 3.3. Concentration dependent biodistribution of C dots injected 
intravenously. Lung images 3 days after injection of (a), 0.33 µM of and (b), 0.3 µM 
of C dots. Images show number and intensity of TRITC-C dots in the lung. The scale 




































Figure 3.4. Time dependent biodistribution of 30 nm C dot in the liver after 
intravenous injection. (a) control was injected with distilled water, imaged one day 
post-injection, (b) 0.33 µM TRITC-C dots imaged one day post-injection, (c) three 
days post-injection, (d) seven days post-injection, (e) 21 days post-injection, and (f) 60 
days post-injection. The scale bar indicates 50 μm. 
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Figure 3.5. (a) Labeling of capillaries with C dots immediately following a tail vein 
injection of TRITC-C dots, fluorescent capillaries containing C dots (arrow) were 
clearly visible in vivo at the base of the dermis via a multiphoton microscopy. Here 
imaging was accomplished using 880nm excitation. Second harmonic generation from 
collagen fibrils is shown in green. Fluorescence emission (500-650 nm) is shown in 
red. The large red structure in the upper left hand corner is from an autofluorescent 
hair follicle. The skin was imaged in vivo using the temporary skin immobilizer as 
described in (Flesken-Nikitin et al., 2005). (b) Labeling of macrophages with C dots. 
Macrophages (arrow) were detected through the skin of a mouse following intradermal 
injection of C dots. (c - f) Sentinel lymph node mapping with C dots. The arrow 
indicates the auxiliary lymph node marked with trypan blue (c). Fluorescent images of 
the node were taken with the Olympus OV 100 system before (d) and at 1 (e) and 60 
(f) minutes after administration of C dots injected at the same site as trypan blue. The 




























Figure 3.6. The stability of C dot fluorescence intensity. (a) The intensity of C dots 
that were incubated at 37°C in vitro only shows a 25% decrease over 4 weeks. The 
data were analyzed by linear regression (Slope; y= -0.7257x + 95.6, R2=0.6536). (b) 
The average intensity of C dots in the liver was fairly stable and unchanged. The 
average intensity (mean ± standard deviation) indicates the average pixel value of C 
dots in cells with particles.  
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This experiment showed that although the particle fluorescence decreased slightly 
over time, this non-specific degradation was only ~25% per month and could not 
result in the net loss of fluorescence seen in vivo (Figure 3.6a).  Although  the  particle 
size (30 nm diameter) is too large for excretion through the kidneys and urinary 
system (Choyke and Kobayashi, 2006), the localization of the particles within the 
mononuclear phagocyte system indicates that the particles may be scavenged and 
cleared by macrophages consistently with results from pulmonary silica particle 
exposure (Adamson et al., 1994; Lee and Kelly, 1992; Oberdorster et al., 2005). This 
possibility is in agreement with our observation that the average dot fluorescence per 
cell remained relatively constant (Figure 3.6b). 
 Having demonstrated the C dots to be a non-toxic and minimally invasive tool 
for in vivo experiments, we sought to demonstrate their capabilities for live animal 
imaging. 
 Multiphoton imaging (Figure 3.5a) of intravenously-injected C dots showed 
appreciable fluorescence within capillaries at the base of the dermis. In addition to 
intravenous injection, C dots were imaged following sub-cutaneous injection and 
found to localize within phagocytic cells within 30 minutes of injection (Figure 3.5b).  
 As a demonstration of the use of C dots as clinical tools for biomedicine, we 
next tested the particles as tracers for sentinel lymph node mapping. After intradermal 
injection of Trypan blue followed by TRITC-based C Dots into the mouse paw, the 
sentinel lymph node was marked by fluorescence in a whole-body imager from thirty 
seconds post-injection and remained visible up to one hour post-injection (Figure 3.5c-
f, and 3.7).  
 The appeal of fluorescent silica nanoparticles as biological probes comes not 
only from their bright and stable fluorescence, but also the ability to tune the particle 






Figure 3.7. Sentinel lymph node mapping with C dots (supplementary images of 
Figure 3.5.c-f). (a) Identification of the lymph node with trypan blue, (b) before C dot 
injection, (c) 30 seconds after C dot injection, (d) one minute post-injection, (e) five 
minutes post-injection, (f) ten minutes post-injection, (g) 30 minutes post-injection, 
and (h) one hour post-injection. Arrows indicate the auxiliary lymph node. The scale 
bar indicates 3 mm. 
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frequently require the labeling of particular cells to facilitate imaging and tracing in 
vivo. Towards that end, cell-penetrating oligopeptides (e.g.  HIV-1  TAT48-57  
(Torchilin et al., 2001)) can be covalently bound to the particle surface to mediate 
cellular uptake (Santra et al., 2005b). We developed conjugation methods for 
functionalizing 30 nm TRITC-based C dots with TAT peptides. These functionalized 
particles were found to be readily endocytosed into intracellular vesicles in mouse 
prostate carcinoma cells (PCN2, Figure 3.8a), while bare particles showed minimal 
uptake under similar conditions (Figure 3.8b).  
 TRITC particle-labeled prostate carcinoma cells were introduced into the body 
intravenously to simulate the release of metastatic cells into the bloodstream by 
extravasation. Using the fluorescent C dot labels, in conjunction with GFP-expressing 
PCN2 cells, the cells were found to localize predominantly in the lung of the mouse, 
where they were imaged via multiphoton imaging (Figure 3.8). This application 
demonstrates the use of these particles as tags for the tracking and identification of 
metastatic cells towards a better understanding of the spread of cancer through the 
body.  
 This protocol was expanded to label primary bone marrow cells to demonstrate 
the versatility of TAT-peptide mediated particle uptake. We exposed TAT-conjugated 
TRITC-based C dots to freshly-harvested bone marrow cells from transgenic mice 
expressing GFP under the control of chicken β-actin promoter. We then administered 
the C Dot-labeled cells to irradiated chimeric mice lacking viable bone marrow cells 
and monitored the distribution of the cells in the body (Figure 3.8d-g). The TAT 
peptide-mediated labeling of these cells proved effective in tracking their fate 
following injection into the body, where they were found to localize predominantly in 





Figure 3.8. Labeling and tracing cells with C dots. PCN2 cells were incubated with 
TAT-conjugated (a) and bare silica (b) TRITC-C dots  for 2 hours at 37 °C, stained 
with membrane-specific DiO-C16 lipophilic probe (green) and imaged by confocal 
fluorescence microscopy. The TAT-conjugated particles show efficient uptake into 
vesicles within the cytoplasm, when compared to the bare silica C dots (arrows). (c) 
Tumor cells expressing GFP (arrow) labeled with TRITC C dots (red) functionalized 
with TAT-peptide oligomers were imaged in the lung by multiphoton microscopy five 
hours after tail vein injection. Multiphoton microscopy bis accomplished using 880 
nm excitation with two broad emission filters (380-550 nm, green and 550-650 nm, 
red). Note that non-specific autofluorescnce and second harmonic generation showing 
lung structure is also visible in the green channel. (d-g) Bone marrow cells (arrows) 
were collected from transgenic mice that carry GFP-driven by chicken β actin 
promoter, labeled with TAT-C dots (red) and imaged in bone marrow smear with 
DAPI labeling (d, e), the liver (f), and the spleen (g) 24 hours after tail vein injection 
of irradiated recipient mice. The bone marrow cells that contain TRITC-C dots are 
yellow (e), while those without C-dot labeling are green (d). (h) Metastatic tumor cells 
labeled with OG488 C dots (green, arrow) and bone marrow cells labeled with TRITC 
C dots (red, arrowhead) were detected in the lung by multiphoton microscopy. The 







Finally, we investigated feasibility of labeling different cell types with C dots of 
different colors. TAT peptide-labeled Oregon Green 488 (OG488) and TRITC-based 
30 nm C dots were incubated with PCN2 and bone marrow cells, respectively. 
Following mixing both cell types and tail vein injection of the combined solution, 
organs were harvested and imaged using multiphoton microscopy. Optical lung 
sections collected five hours post-injection showed that both cancer cells (green) and 
the bone marrow cells (red) can be easily detected (Figure 4.8h). Interestingly, both 
cell types are commonly found to be co-localized, indicating possible functional 
interactions between bone marrow and metastatic cells. 
 
3.5 Discussion 
Biological safety concerns are among the principle roadblocks on the way 
towards implementation of imaging nanoparticles into clinical practice. For example, 
the issue of QD toxicity caused by heavy metals (Cd, Pb, etc) has been raised and is of 
particular importance for long-term in vivo experiments. Recent studies have observed 
cytotoxicity in hepatocytes (a major target of Cd+2 injury), caused by the release of 
Cd+2 ions from the Cadmium selenide (CdSe) QD core due to oxidization by air or UV 
light (Derfus et al., 2004; Hoshino et al., 2004; Kirchner et al., 2005; Shiohara et al., 
2004). Researchers have tried to combat this by applying surface coatings such as 
ZnS, polymers, or surfactants to reduce the release of heavy metals, but these 
treatments provide only partial protection to the core (Alivisatos et al., 2005). 
Additional research has shown that certain QD surface coatings (e.g. 
mercaptoundecanoic acid) can actually decrease cell viability in cell culture studies 
(Hoshino et al., 2004). These problems have prompted us to test if recently described 
bright core-shell silica nanoparticles (C dots) could be a feasible alternative to QDs in 
various biomedical imaging applications. 
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 Available reports on toxicological effects of silica concentrate on pulmonary 
exposure (rather than intravenous) to simulate human exposure to particulates in air. 
Toxicological effects of colloidal (amorphous) silica are characterized fairly well as 
being less toxic than crystalline forms in experimental animals (Kelley and Lee, 1990; 
Oberdorster et al., 2005). However, there are studies suggesting that inhalation of 
materials such as colloidal silica by mice induces dose- and size-dependent pulmonary 
effects, with ultrafine (<100 nm) particles inducing greater lung inflammation and 
tissue damage than larger particles (Kaewamatawong et al., 2005). Generally, these 
effects were characterized by an accumulation of particles in alveolar macrophages, 
neutrophilic infiltration, and type II epithelial cell hyperplasia (Lee and Kelly, 1992; 
Lee and Kelly, 1993).  
 In our studies, we have found that 30 nm C dot silica nanoparticles 
administered by tail-vein injection (rather than inhalation) show no apparent toxicity 
in mice when compared with control populations, supporting the notion that colloidal 
(amorphous) silica is less toxic than crystalline silica. The discrepancy with the 
previous study by Kaewamatawong et al. (Kaewamatawong et al., 2005) is likely due 
to the different administration route of our particles. Thus, functional core-shell silica 
nanoparticles may represent a valuable materials platform for in vivo studies of 
fundamental biology as well as the development of clinical applications for the 
particles.  
 We chose to employ multiphoton microscopy for much of the in vivo imaging 
experiments because of its ability to image deeply in tissue and that it also allows for 
simultaneous collection of morphological information from intrinsic tissue emitters 
and collagen second harmonic (Zipfel et al., 2003). In addition, the localized 
excitation eliminates photobleaching outside of the focal plane compared to single 
photon wide field or confocal microscopy (Zipfel et al., 2003). This allowed us to 
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determine the location and trafficking of the particles within the circulatory system as 
well as within the tissue of the mouse with high signal-to-noise, and may be useful in 
the future for imaging of, e.g., tumor vasculature or ischemia.  
 One area where the development of nanoscale tools is of particular interest is 
cancer research and diagnosis (Santra et al., 2005a). The convergence of sensitive and 
stable imaging agents(Burns et al., 2006a) with advancements in multiphoton (Zipfel 
et al., 2003) and whole-body imaging can facilitate studies of both fundamental cancer 
biology as well as potentially advancing clinical techniques. For example, early 
detection of cancer dramatically increases survival rates and the use of targeted 
multifunctional nanoparticle assays with advanced imaging techniques may decrease 
the detection limit for tumor size to allow treatments to be targeted to tumors before 
they pose a major threat to the patient.  
 As well, these particles may allow for greater sensitivity in clinical 
applications such as sentinel lymph node mapping which has been proven to be an 
effective method for diagnosis of tumor metastasis and is currently the protocol of 
choice to determine the likely site of tumor progression (Jakub et al., 2003). In this 
approach a dye or other tracer is injected in the tumor locale, and visualized as it 
drains into the lymphatic basin. The sentinel lymph node is the node which collects 
this tracer and can then be removed for biopsy. Further analysis of the node reveals 
whether or not any metastatic cells have also drained into the node and provides 
oncologists with an effective means to monitor the spread of the cancer through the 
body. Our study demonstrates that the bright and stable fluorescence of the 30 nm C 
dots make them excellent imaging agents for the identification of sentinel lymph 
nodes.  
 Nanoparticle-based probes also facilitate studying fundamental cancer biology. 
For example, fluorescence imaging provides an excellent tool for following the fate of 
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metastatic cells as they leave the tumor milieu (Voura et al., 2004). By surface-
functionalizing the C dots with cell-penetrating peptides (Santra et al., 2005b; 
Torchilin et al., 2001), we were able to internally label the cells through particle 
uptake and track the metastatic prostate carcinoma cells through the body. This 
method may be employed in the future to study the trafficking of different cancer cells 
and to determine their response to therapeutic interventions. 
 One of the rapidly developing areas of metastasis research is understanding of 
interactions between metastatic and bone marrow cells (Kaplan et al., 2005; Ren et al., 
2008). To test for such interactions, we developed a multi-color labeling experiment 
using different colored TAT-conjugated C dots to label prostate cancer cells and bone 
marrow cells in vivo. We then injected both particles and were able to detect their co-
localization by multiphoton microscopy. This work demonstrates versatility of TAT-C 
dots as tools for the labeling of various cell types and their particular suitability to 
study interactions between metastatic and bone marrow cells. 
 In this paper, we have demonstrated the safety, efficacy and utility of 
fluorescent core-shell silica nanoparticles (C dots) for biomedical applications from 
research to clinically relevant tools for oncology and beyond. These experiments point 
to the use of these particles as an appealing alternative to QDs for a variety of in vivo 
applications including immunolabeling, targeted imaging, and cell tracking. Moreover, 
recent work has shown that the C dot architecture can be built upon further to develop 
core-shell particles incorporating multiple dye species. One application of these 
particles is the creation of quantitative ratiometric sensors for analytes such as pH 
(Burns et al., 2006b) which could be of interest for probing the growth of tumors in 
vivo. In the future, the modular nature of the core-shell architecture may allow creation 
of multifunctional silica particles, a concept referred to as “lab on a particle” (Burns et 
al., 2006a), incorporating, e.g., imaging, drug delivery, targeting, and sensing 
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capabilities into a single probe. In turn, this may lead to the production of highly-
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Conclusion and future prospects  
 
4.1. Mouse model of soft tissue sarcoma and its application for histogenesis and 
pathogenesis studies 
By using conditional inactivation of p53 and Rb tumor suppressor genes in 
dermal connective tissue we established a new mouse model of soft tissue sarcoma 
(STS). After subcutaneous injection of AdCMVCre, mice with floxed p53 and Rb 
mainly developed undifferentiated pleomorphic sarcomas (UPS), also known as 
malignant fibrous histiocytomas (MFH), which are the common human STS. 
Sarcomas in this temporally and spatially controlled mouse model morphologically 
closely resemble human STS and contain the most common genetic alterations, that is 
of p53 and Rb mutations, typical for human STS. Generation of this model has 
addressed a lack of accurate animal systems to study STS with complex genotypes and 
UPS in particular.  
Our model is very useful for future exploration of the molecular mechanism of 
sarcomagenesis associated with p53 and Rb deficiency. 
Our mouse model demonstrates that a development of STS is a result of 
cooperation of p53 and Rb inactivation. Several recent reports support this notion. It 
has been shown  that osteosarcoma development is dependent on the loss of p53 and 
potentiated by the loss of Rb using a mouse model with Osterix-Cre-mediated deletion 
of p53 and Rb (Berman et al., 2008; Walkley et al., 2008). Their acceleration effect 
has also been reported in another sarcoma model induced by Prx1-Cre expression in 
mesenchymal cells of mouse embryonic limbs (Lin et al., 2009). Importantly, our 
model allows studying roles of p53 and Rb in adult dermal connective tissue cells.  
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We found that  the sarcomas in our model overexpress Cxcr4 that is thought to 
be correlated with poor progression in a variety of malignancies (Muller et al., 2001; 
Oda et al., 2006; Strahm et al., 2008; Taichman et al., 2002). We have confirmed this 
observation with a human sarcoma tissue array, which shows high expression in UPS 
compared to dermatofibrosarcoma or fibrosarcoma. A recent work with a large series 
of human STS also has shown that CXCR4 expression in STS, including UPS, was 
significantly higher than that in normal tissues and higher levels of expression 
correlated with poorer prognosis (Oda et al., 2009). This observation further confirms 
the close resemblance of our model with human STS. Importantly, since it has been 
reported that CXCR4 is negatively regulated by P53 in breast cancer (Mehta et al., 
2007), our model may be very valuable for evaluation of similar molecular mechanism 
in STS. Such studies may uncover a link between inactivation of p53 and the cancer 
progression, including metastasis.  
Since MFH identified as a neoplasm containing cells with features of   
fibroblast and macrophage/histiocyte differentiation (Kauffman and Stout, 1961; 
O'Brien and Stout, 1964; Ozzello et al., 1963), the issue of its cell of origin has been 
controversial. Recent studies have mainly supported a view that this type of STS 
originates from fibroblasts or mesenchymal stem/progenitor cells (Fu et al., 1975; 
Hoffman and Dickersin, 1983; Mackall et al., 2002; Nikitin, 1993; Takeya et al., 
1995). Consistent with this notion, by using bone marrow transplantation chimera 
model, we demonstrated that sarcomas, UPS/MFH originate from local resident 
connective tissue cells. Importantly, our observation does not support an earlier study 
(Li et al., 2007) indicating that STS may arise from bone marrow derived cells 
directly. In their model, STS, mostly fibrosarcomas, spontaneously developed in aged 
mice 18 to 24 months after bone marrow transplantation. Unfortunately, direct 
comparison of these neoplasms with our model is complicated because genetic 
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alterations initiating sarcomas described by Li et al. are unknown. Furthermore, 
morpho-functional similarities between sarcomas observed in both studies remain 
unclear. Future research should determine if all dermal MSC are maintained locally or 
bone marrow-derived cells contribute to their replenishment.   
Using such properties as the plastic adherence and the low level of Sca-1 
expression, we isolated dermal MSC and demonstrated their increased transformation 
potential, as comported to more differentiated connective tissue cells of the dermis, 
after inactivation of p53 and Rb. The importance of this observation is threefold: (1) 
dermal mesenchymal stem cells can be isolated by the plastic adherence and Sca-1low 
fraction, (2) transformation induced by inactivation of p53 and Rb with AdCMVCre 
occurs preferentially in dermal MSC, (3) these transformed MSC may be a cell of 
origin of STS. Several studies have reported that sarcomas originate from MSC (Li et 
al., 2007; Matushansky et al., 2007; Tolar et al., 2007). However, since bone marrow 
MSC were used in those experiments, their relevance to natural course of the disease 
has been uncertain.  
As described above, our mouse model closely resembles human STS according 
to a number of morphological and molecular features. We anticipate that use of 
comparative oncogenomic approach suggests many clues to pathogenesis of human 
STS. By genome wide gene expression profiling and array comparative genomic 
hybridization, we may be able to identify potential critical genes and pathways and 
explore molecular mechanisms essential for sarcomagenesis. Recently, Matushansky 
et al. (Matushansky et al., 2007) has indicated that UPS/MFH may develop from  
human MSC transformed via inhibition of Wnt signaling. This suggests that genes 
associated with Wnt pathway may be selective candidates for further studies. 
We demonstrated that UPS/MFH contains a large number of infiltrating 
macrophages which are derived from bone marrow cells according to bone marrow 
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transplantation chimera model. However, the role and mechanism of macrophage 
infiltration in sarcomagenesis remain unclear. This is of particular interest because it 
has been reported  that in many cancers, neoplastic cells  produce various chemokines 
which recruit many inflammatory cells, including macrophages, which, in turn,  may 
facilitate  tumor growth or cancer metastasis (Bingle et al., 2002). It has been reported 
that human derived MFH cells produced monocyte chemoattractant protein-1 (MCP-1) 
that is released by tumor cells as well as fibroblasts, endothelial cells, and 
macrophages (Takeya et al., 1995; Takeya et al., 1991). Checking MCP-1 expression 
in our sarcomas will be a good starting point in this study. Besides MCP-1, other 
chemokines including macrophage-colony stimulating factor (M-CSF or CSF-1) and 
vascular endothelial growth factor (VEGF) will be additional candidates to study the 
mechanism of macrophage infiltration and its roles in sarcoma development.  
In order to isolate dermal MSC we used two main characterization of MSC, 
their plastic adherence and the low level of Sca-1 expression. The development of 
fluorescence activated cell sorting (FACS) technique and specific cells surface 
markers allow for an advanced cell based analysis and isolation of pure cell 
population. Unlike hematopoietic stem cells, cell surface markers for isolation of MSC 
have not been studied well. Although several markers including Sca-1, c-kit, CD29, 
CD49a and CD44 have been suggested for MSC isolation (Baddoo et al., 2003; Sun et 
al., 2003), there are no standard markers established. Therefore, identification and 
testing of additional candidate markers is required for further enrichment of dermal 
MSC. Moreover, further development of MSC differentiation assays may provide 
important clues towards explaining diversity of STS histological patterns.   
Given increasing appreciation of potential contributions of p53 and Rb in 
regulation of stem cells, it will be of a particular interest to study their roles in MSC. 
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As the first steps, analyses of senescence, apoptosis, proliferation and self-renewal of 
MSC after inactivation of p53 and Rb will be performed.  
Finally, we believe that our STS model can serve as a valuable tool for 
identification of valid therapeutic targets and development and testing of novel 
therapeutic approaches. For example, our model would allow preclinical testing of 
STS treatment by Cxcr4-siRNA administration. 
 
4.2 Applications of core-shell silica nanoparticles in biomedicine and for in vivo 
imaging study of sarcoma origin 
In chapter 3, we described several successful applications of fluorescent core-
shell silica nanoparticles (known as C dots) as a powerful imaging tool in 
biomedicine. Overall in the study, we showed C dots have no apparent toxicity in mice 
and can be used as a valuable tool in imaging or labeling blood vessels and 
macrophage and mapping sentinel lymph nodes. Furthermore, C dots can be 
efficiently functionalized for particular applications, such as TAT-peptide conjugation 
for enhanced cell penetration, with their ability to tune the particle surface. We finally 
showed the feasibility of labeling different cell types with multiple colors of C dots.  
These data indicate that C dots can be replaced with quantum dots, which are 
commercially available and widely used in many imaging applications in biomedicine, 
with non-toxicity, and high sensitivity, resolution, and stability. One of the advantages 
of C dots is their feasible tunability of the particle surface. This allows increasing 
targeting selectivity and multifuctionality in therapeutic strategies. In particular, these 
nanoprobes will improve cancer imaging technologies, starting with the effective early 
detection of cancer and metastasis lesions and the proficient therapeutic target 
efficiency to cancer lesions. Beyond cell labeling, targeting imaging and cell tracking, 
C dots will represent an effective tool in the new advanced nanomedicine with the 
 127 
 
modular nature of the C dots architecture that allows highly integrated and functional 
nanoparticles platforms.   
We have successfully visualized blood vessels and individual cells marked 
with C dots in the dermis of mice in vivo through a multiphoton microscopy. Based on 
these observations, we expect that the in vivo imaging will allow monitoring behavior 
of connective tissue cells after inactivation of p53 and Rb. These studies will provide 
more clues regarding cellular origin of sarcoma to clarify the correlation between 
tumor cells and macrophages. In order to further test the hypothesis that UPS/MFH 
originates from MSC, several in vivo imaging experiments will be applied with a 
variety of fluorescent markers. First of all, chimeric mice carrying p53loxP/loxP and 
RbloxP/loxP that contain RFP-expressing bone marrow cells derived from donor 
transgenic RFP mice can be administrated with AdCMVCre-GFP to induce sarcomas. 
A chronic-transparent window (skin-flap), where virus was injected, will be visualized 
by the optical approach with a multiphoton microscopy. This experiment will show the 
behavior of adenovirus-targeted cells and macrophages individually or their 
interactions at the stage of tumor initiation. The second approach will be the imaging 
of macrophage motility towards sarcoma cells orthotopically injected into mouse 
dermis. Following labeling dermal resident macrophages with red-color C dots by 
intradermal injection, sarcoma cells labeled with green-color C dots will be 
administrated into the dermis nearby where macrophages are labeled. Additionally, we 
might be able to observe that macrophage could be located nearby visualized blood 
vessels marked with red-color C dots injected intravenously. Macrophages are known 
to be a stimulant of angiogenesis in tumor progress (Condeelis and Segall, 2003; Jain 
et al., 2002). Their association could provide us a key in how macrophage affect in 
sarcoma development.  
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Furthermore, monitoring reductions in tumor size or metastasis after treatment 
of tumors by therapeutic agents labeled with fluorescent nanoparticles, for example, 
injection of CXCR4-siRNA labeled with C dots, by the whole body imaging will 
provide us visualized cancer treatments which deliver some clues to prevent side 
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